

chain nodes :

6 12 15 17 24 25 27 28 29

ring nodes :

1 2 3 4 5 7 8 9 10 11 18 19 20 21 22 23

chain bonds :

4-6 6-7 9-12 10-15 17-27 18-29 22-25 23-24 27-28 28-29

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 18-23 18-19 19-20 20-21 21-22
22-23

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-27 18-23
18-19 18-29 19-20 20-21 21-22 22-23 22-25 23-24 27-28 28-29

exact bonds :

6-7

G1:Ph,Cy

G2:C,O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS


L1 STR



G1 Ph,Cy
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10671326amendG.str



chain nodes :
6 12 15 17 18 25 26
ring nodes :
1 2 3 4 5 7 8 9 10 11 19 20 21 22 23 24


chain bonds :
4-6 6-7 9-12 10-15 17-18 18-19 23-26 24-25
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11 19-20 19-24 20-21 21-22 22-23
23-24
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15 17-18 18-19
19-20 19-24 20-21 21-22 22-23 23-24 23-26 24-25
exact bonds :
6-7

G1:Ph,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 15:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:CLASS 26:CLASS 27:CLASS

L2 STRUCTURE UPLOADED



=> d 12
L2 HAS NO ANSWERS
L2 STR



G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10671326amend2.str



chain nodes :

6 12 15

ring nodes :

1 2 3 4 5 7 8 9 10 11

chain bonds :

4-6 6-7 9-12 10-15

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 7-8 7-11 8-9 9-10 9-12 10-11 10-15

exact bonds :

6-7

G1:Ph,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 15:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



G1 Ph,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:51:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 10:51:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 119 TO ITERATE

100.0% PROCESSED 119 ITERATIONS
SEARCH TIME: 00.00.01

24 ANSWERS

L5 24 SEA SSS FUL L1

=> s 12
SAMPLE SEARCH INITIATED 10:51:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 4 TO 200

L6 4 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 10:51:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 121 TO ITERATE

100.0% PROCESSED 121 ITERATIONS
SEARCH TIME: 00.00.01

76 ANSWERS

L7 76 SEA SSS FUL L2

=> s 13
SAMPLE SEARCH INITIATED 10:51:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS
SEARCH TIME: 00.00.01

38 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 436 TO 1204
PROJECTED ANSWERS: 391 TO 1129

L8 38 SEA SSS SAM L3

=> s 13 full
FULL SEARCH INITIATED 10:51:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 861 TO ITERATE

100.0% PROCESSED 861 ITERATIONS
SEARCH TIME: 00.00.01

831 ANSWERS

L9 831 SEA SSS FUL L3

=> fil hcaplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE TOTAL
ENTRY SESSION
484.85 485.06

FILE 'HCAPLUS' ENTERED AT 10:52:02 ON 29 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23
FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15
L10 1 L5

=> d ed abs ibib hitstr

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 09 Apr 2004
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds..
 e.g. I [A = C, C(=O), N (with proviso, that at least one A = C); B = O, NR2, S(O)C(=O), C1(O), C1(S), C1(NR3); P = O, I; q = 0, 1; r = 0, 2; R2 = H, S(O)R4, CHO, Cl-8-alkyl, Cl-8-alkenyl, Cl-8-alkynyl, Cl-8-alkoxy, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R3 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, Cl-8-alkyl, Cl-8-alkenyl, Cl-8-alkynyl, Cl-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(O)NR3R3, Cl-8-alkyl, Cl-8-alkenyl, Cl-8-alkynyl, etc.; D = D1, D2, D3, D4, S = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = Cl-4-alkyl, Cl-8-alkyl, Cl-8-alkenyl, Cl-8-alkynyl, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C, N, O, S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative I was prepared from N-(desmethylerythromycin), via N-alkylation with HCl-boron C12H207 and cycloaddn. with azide III.

ACCESSION NUMBER: 200429209 HCAPLUS

DOCUMENT NUMBER: 1401321158

TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents

INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; McConnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.

PATENT ASSIGNEE(S): Riker-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200429066	A2	20040408	WO 2003-U530478	20030925
WO 200429066	C1	20040513		
WO 200429066	A3	20040826		

W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,


L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PAGE 1-B




RN 677726-86-2 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,6,6-trideoxy-3-[(2-[(1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methoxy]ethyl)methylamino]-B-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



540/454

514

IT 677726-16-0P 677726-18-0P 677726-28-2P
 Page 929/11/2005

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SY, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TZ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, GA, GW, IL, MT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, OM, GA, GW, MI, MN, NE, SN, TD, TG

US 200517334 A1 2005050908 US 2003-571326 20030925
 CA 2500158 AA 20040408 CA 2003-2500158 20030926
 EP 1543017 A2 20050622 EP 2003-770506 20030926
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TA, BG, CZ, EE, HU, SK


PRIORITY APPLN. INFO.: US 2002-414207 P 20020926
 US 2003-448216P P 20030219
 WO 2003-U530478 W 20030925

OTHER SOURCE(S): MARPAT 140:321158

IT 677726-86-2P 677726-86-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (uses); (prepn. and hydrolysis of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-85-1 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,6,6-trideoxy-3-[(2-[(1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methoxy]ethyl)methylamino]-B-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



540/454


PAGE 1-A

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 677726-77-1P 677726-78-2P 677726-79-3P
 677726-80-6P 677726-82-8P 677726-87-3P
 677726-88-4P 677727-78-5P 677727-79-6P
 677727-80-9P 677727-81-0P 677727-82-1P
 677727-83-2P 677727-90-1P 677727-92-3P
 677727-95-6P 677727-96-7P 677727-97-8P
 677727-99-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (uses); (prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-16-8 HCAPLUS
 CN Erythromycin, N-demethyl-1-[3-[(1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B





544/137

514/236.2





RN 677726-18-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[4-1-[(5R)-3-
 [3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 677726-28-2 HCPLUS
 CN Erythromycin, N-[3-1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-
 oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.





RN 677726-77-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[4-1-[(5R)-2-
 oxo-3-(5-quinoliny)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-78-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[4-1-[(5R)-3-
 [3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-79-3 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]butylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-80-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(1-[(5R)-3-(4-acetylphenyl)-
 2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl)methylamino]-
 3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-
 methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-82-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)methoxy]ethyl)methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677726-87-3 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)methoxy]ethyl)methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.







RN 677726-89-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(4-methyl-2-thiazolyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)propyl]amino]- β -D-xylo-hexopyranosyl oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677727-79-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-





RN 677727-80-9 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(4-dimethylamino)-2-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)propyl]methylamino]- β -D-xylo-hexopyranosyl oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 a-L-ribo-hexopyranosyl oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(4-methyl-2-thiazolyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)propyl]amino]- β -D-xylo-hexopyranosyl oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677727-79-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)propyl]methylamino]- β -D-xylo-hexopyranosyl oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 677727-81-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(3-fluoro-4-[(2-hydroxyethyl)methylamino)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)propyl]methylamino]- β -D-xylo-hexopyranosyl oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-82-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3,5-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl)methylamino]-β-D-xylo-hexopyranosyl]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-83-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3,4-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl)methylamino]-β-D-xylo-hexopyranosyl]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-90-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(4-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl)methylamino]-β-D-xylo-hexopyranosyl]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-92-3 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3,4-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl)methylamino]-β-D-xylo-hexopyranosyl]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-95-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-1-[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-96-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethoxy]carbonyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-97-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethoxy]carbonyl]amino]-β-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-99-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-1-[(5R)-3-[4-(dimethylamino)sulfonyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=> s 17

L11 1 L7

=> d ed abs ibib hitstr

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 09 Apr 2004

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I ($A = C$; $B = O$, NR₂, S(O)_r, C(=O), C(=S), C(=NOR₃); $p = 0$ –1; $q = 0$ –1; $r = 0$ –2; R₂ = H, S(O)_rR₄, CHO, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, Cl-8-alkoxy, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR₂R₂ = 5 to 9-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R₃ = H, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, Cl-8-acyl, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR₃R₃ = 5 to (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R₄ = H, NR₃R₃, NR₃OR₃, NR₃CR₃, C(=O)NR₃R₃, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, etc.; D = D₁, D₂, D₃, D₄; E = di- or para-substituted Ph, substituted 4-vinylphenyl; G = Cl-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, Cl-8-alkoxy, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C, N, O; dashed line = single or double bond) or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with HC₁pbond.CC(=O)CH₂CO₂Et, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004292026 HCAPLUS

DOCUMENT NUMBER: 140321158

TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents

INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; McConnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIKXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200429066	A2	20040408	WO 2003-US30478	20030925
WO 200429066	C1	20040513		
WO 200429066	A3	20040826		


V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



IT 677726-17-9P 677726-31-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and hydrolysis of) preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents

RN 677726-17-9 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-fluoro-4-(4-mercaptoethyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino)-8-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MX, MN, MW, MX, MZ, NJ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, KZ, KE, LS, MW, MZ, SD, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, LU, NL, SE, MC, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

US 200517334 A1 2005050908 US 2003-671326 20030925

CA 2500158 AA 20040408 CA 2003-2500158 20030926

EP 1543017 A2 20050622 EP 2003-770506 20030926

R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-414207P P 20020926

US 2003-448216P P 20030219

WO 2003-US30478 W 20030925

OTHER SOURCE(S): MARPAT 140:321158

IT 677726-18-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation and N-dealkylation of) preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents

RN 677726-18-7 HCAPLUS

CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-mercaptoethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-31-7 HCAPLUS


1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-fluoro-4-(4-mercaptoethyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino)-8-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 677726-16-0P 677726-18-0P 677726-26-0P
 677726-27-1P 677726-28-2P 677726-29-3P
 677726-30-6P 677726-33-9P 677726-34-0P
 677726-35-1P 677726-36-2P 677726-46-4P
 677726-47-5P 677726-48-6P 677726-49-7P
 677726-50-0P 677726-51-1P 677726-52-2P
 677726-53-3P 677726-54-4P 677726-55-5P
 677726-57-7P 677726-58-8P 677726-60-2P
 677726-62-4P 677726-63-5P 677726-65-7P
 677726-66-8P 677726-68-0P 677726-70-4P
 677726-72-6P 677726-73-7P 677726-74-8P
 677726-75-9P 677726-76-0P 677726-77-1P
 677726-78-2P 677726-79-3P 677726-80-6P
 677726-81-7P 677726-82-8P 677726-83-9P
 677726-84-0P 677726-89-5P 677726-90-8P
 677727-77-4P 677727-78-5P 677727-79-6P
 677727-80-9P 677727-81-0P 677727-82-1P
 677727-83-2P 677727-84-3P 677727-85-4P
 677727-86-5P 677727-87-6P 677727-88-7P
 677727-89-8P 677727-90-1P 677727-91-2P
 677727-92-3P 677727-93-4P 677727-94-5P
 677727-95-6P 677727-98-9P 677727-99-0P
 677728-00-6P 677728-01-7P 677728-02-8P


PAGE 2-A




RN 677726-18-0 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,10,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl)methylamino]-B-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-03-9P 677726-04-0P 677726-42-9P
 678182-71-3DP, trans-cyclohexanol isomers
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)
 CN Erythromycin, N-[3-1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-26-0 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-B-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-27-1 HCAPLUS
 CN Erythromycin, N-[2-1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 677726-29-2 HCPLUS
 CN Erythromycin, N-[3-[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-29-3 HCPLUS
 CN 1-Oxa-6-azacycloheptadecan-15-one, 11-[3-[[2-[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-30-6 HCPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A







RN 677726-33-9 HCPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A








RN 677726-34-0 HCAPIUS
 CN Erythromycin, N-[2-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-35-1 HCAPIUS
 CN Erythromycin, N-demethyl-N-[2-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-46-4 HCAPIUS
 CN 1-Oxido-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6,10-trideoxy-3-[(2-[(1-[(2-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-9CI] (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

RN 677726-36-2 HCAPIUS
 CN Erythromycin, 3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy]-N-demethyl-N-[2-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A

RN 677726-46-4 HCAPIUS
 CN 1-Oxido-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6,10-trideoxy-3-[(2-[(1-[(2-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-9CI] (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

Page 2029/11/2005






RN 677726-47-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-49-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[2-[1-[(5R)-3-[(2-[(acetyloxy)ethyl]methylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-48-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-50-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 677726-51-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-52-2 HCPLUS
 CN Erythromycin, N,N-didemethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 677726-53-3 HCPLUS
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)-N-demethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-54-4 HCPLUS
 CN Erythromycin, 3-de{(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy}-N-demethyl-N-[2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 677726-55-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribopyranosyl)oxy]-2-ethyl-11,4,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[4-(dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A








RN 677726-57-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[(3-
 fluoro-4-(1H-pyrcol-1-yl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)ethyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-60-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[(3-
 fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)ethyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-58-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-1-[(5R)-3-[(4'-cyano-2-
 fluoro-1,1'-biphenyl)-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-
 4-yl)ethyl]methylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-
 [(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-62-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[(4-
 [(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)-3-fluorophenyl]-2-oxo-5-
 oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino)-β-D-
 xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.





RN 677726-63-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-1-[(5R)-3-[(4'-cyano-3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino)-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-
 [(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-65-7 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-
 fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-
 oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]-β-D-
 xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.





RN 677726-66-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(
 4-[(methylsulfonyl)amino]sulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-
 1H-1,2,3-triazol-4-yl)ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-68-0 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[1-[(5R)-3-(
 aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-
 [(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-70-4 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[1-[(5R)-3-(
 aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-
 [(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 67726-72-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-
 [[(dimethylamino)methylene]amino)sulfonamido]phenyl]-2-oxo-5-
 oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-β-D-
 xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.





RN 67726-73-7 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(3,4-
 dihydrophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 67726-74-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3,5-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 67726-75-9 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(2-[1-[(5R)-3-(1,3-benzodioxol-
 5-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl)methylamino]-3,4,10-trihydroxy-β-D-xylo-hexopyranosyl)oxy]-13-
 [(2,6-dideoxy-3-C-methyl-3-O-ethyl-α-L-ribo-hexopyranosyl)oxy]-2-
 ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 677726-76-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-1-[(5R)-2-
 oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-77-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[4-1-[(5R)-2-
 oxo-3-(5-quinolinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 677726-78-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-1-[(5R)-3-[3-
 fluoro-4-(4-morpholinyl)phenyl]-2-oxo-3-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]butyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-79-3 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-
 [1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)butyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-80-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(4-[(1-[(5R)-3-(4-acetylphenyl)-
 2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)butyl]methylamino)-
 3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-
 methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(2R,3S,4R,5R,8R,10R,11R,12S,13S,
 14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-81-7 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-82-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-
 [1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)butyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-83-9 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-
 [1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)-1-propenyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-84-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)-1-
 propenyl)methylamino]- β -D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 677726-89-5 HCPLUS
 CN 2H-Omacyclotetradecene[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-
 3-[(2-1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-
 oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)-ethyl]methylamino]- β -D-
 xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-90-8 HCPLUS
 CN 2H-Omacyclotetradecene[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-
 3-[(2-1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl)-ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-77-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(1-[(5R)-3-(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl)-ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-78-5 HCPLUS


L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl-3-[1-[(5R)-3-
 (4-methyl-1-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]propyl]amino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677727-79-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-80-9 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-(4-
 dimethylamino)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677727-81-0 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 677727-82-1 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-(3-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-83-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-1-[(5R)-3-(3,4-
 dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-84-3 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(2-
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-85-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-86-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(4-
 fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-87-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-
 hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-88-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-
 hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-89-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 1-B






RN 677727-90-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[(4-
 fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677727-91-2 HCAPLUS
 CN 1-Oxa-8-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,6-ditrideoxy-2-[2-(1-[(5R)-3-(3,4-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 67727-93-4 HCAPUS
 CN 1-Oxa-6-azoxycyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribofuranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-hexamethyl-11-[(3,4,6-trideoxy-3-[2-(2-[1-[(5R)-3-[2-fluoro-4-[(4-quinoxalinylmethyl)amino]methyl]1,1'-biphenyl-4-yl]methyl]2-oxo-5-oxazolidinylmethyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

Absolute stereochemistry.





RN 67727-95-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[4-[(1-[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl]methylamino)-beta-D-xylo-hexopyranosyl]oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 67727-98-9 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[(1-[(5R)-3-(4-[(dimethylamino)sulfonyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino)-beta-D-xylo-hexopyranosyl]oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 67727-99-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-(4-[(dimethylamino)sulfonyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino)-beta-D-xylo-hexopyranosyl]oxy]-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 67728-00-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[(1-[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino)-3,4,6-trideoxy-beta-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-01-7 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[[2-[1-[(5R)-3-cyclopentyl-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino)-3,4,6-trideoxy- β -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-[1-[(5R)-2-oxo-3-(4-(trifluoromethyl)phenyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino)- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-02-8 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-[1-[(5R)-2-oxo-3-(4-(trifluoromethyl)phenyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino)- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-03-9 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-[1-[(5R)-2-oxo-3-(4-(trifluoromethyl)phenyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino)- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







PAGE 1-B




RN 677728-04-0 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[{2-[1-[(5R)-3-(3-fluoro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl}-1H-1,2,3-triazol-4-yl]ethyl]amino)- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677729-42-9 HCAPIUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678182-71-3 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(trans-4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-

Absolute stereochemistry.



Ngrazier 10671326Amend2

=> s 19
L12 41 L9

=> d ed abs ibib hitstr 1-41

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 16 Sep 2005
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides macrocyclic azithromycin compds. I and II, wherein T is macrolide; R1 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl ester, amide, thio-acyl, thio-ester, amine; R2 is H, alkoxy, D is single bond, alkyl, alkynyl, acyl, ester, amide, imine, sulfonyl, amine, thio-acyl, thio-ester; E is aromatic heterocycle, carbocycle, CO, CO₂, amide, imine; F is single bond, alkyl, alkenyl, alkynyl; G is aryl, heterocyclic, bicyclic, tricyclic, aryl, were prepared as antibacterial, anti-proliferative, prokinetic, and antiinflammatory agents. Thus, III was prepared and used as antibacterial, anti-proliferative, and antiinflammatory agent.

ACCESSION NUMBER: 20051004760 HCAPLUS

DOCUMENT NUMBER: 143-306499

TITLE: Preparation of macrocyclic azithromycin compounds as antibacterial, anti-proliferative, and antiinflammatory agents

INVENTOR(S): Farmer, Jay J.; Bhattacharjee, Ashoke; Chen, Yi; Goldberg, Joel A.; Ippolito, Joseph A.; Kanyo, Zoltan F.; Lou, Rongliang; Oyelere, Adegboyega K.; Sherer, Edward C.; Sutcliffe, Joyce A.; Wang, Deping; Wu, Yusheng; Du, Yanning

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 333 pp.

CODEM: PIXAD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085266	A2	20050915	WO 2005-US6082	20050225
W: AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, NG, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		US 2004-548280P	P	20040227
		US 2004-575949P	P	20040601


IT 864529-35-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 864529-35-1 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]methyl]methylamino)-8-D-wylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-B

L12 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



PAGE 2-A

PAGE 2-B



IT 864529-87-7



RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of macrocyclic azithromycin compds. as antibacterial, anti-proliferative, and antiinflammatory agents)

RN 864529-57-7 HCAPLUS

CN 2-Oxazolidinone, 3-[2-fluoro-4-[(methylsulfonyl)oxy]methyl][1,1'-biphenyl]-4-yl]-3-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 08 Sep 2005
 GI



AB Amidoxime and amidine oxazolidinones I [wherein X = certain O-containing five-membered heterocycle; Y = CH2OH, CH2NHAc, etc.; Y1 - Y2 = CH, N, N(O) or CF; G = CH2, etc.; U = CH2, CF2, O, S, SO or SO2; R2 = H or alkyl; V = N or C; Z = H, OH, alkoxyl, etc., or pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. For instance, II, which showed antibacterial activity with MIC values of 1-4 μ g/ml against *S. aureus*, *S. pyogenes* and *S. pneumoniae*, was synthesized from Me bromacetate and 2-amino-5-nitrophenol in eight steps. The invented compds. are potentially useful for the treatment of bacteria infectious diseases.

ACCESSION NUMBER: 2005-9795647 HCAPLUS

DOCUMENT NUMBER: 1431286413

TITLE: Preparation of oxazolidinone compounds as antibacterial agents

INVENTOR(S): Gordiev, Mikhail Fedorovich; Jain, Rama; Josyula, Varu Prasad Venkata Nagendra; Luehr, Gary Wayne

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082897	A1	20050909	WO 2005-IB102	20050117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RU: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L12 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PRIORITY APPLN. INFO.: US 2004-540214P P 20040128
 IT 864073-59-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazolidinones as antibacterial agents)
 RN 864073-59-6 HCAPLUS
 CN 2H-1,4-Benzoxazin-3(4H)-one, 4-methyl-7-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)-, 3-(O-methyloxime) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 08 Jul 2005
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, etc.; M = (un)substituted alkyl, alkenyl, alkynyl; X = O, -N(O)-, -O-N=, etc.; L = (un)substituted alkyl, alkenyl, alkynyl; R1 = halo, CF3, NO2, etc.; R2 = CN, halo, CF3, etc.; R3 = OR4, NR4R4, C(O)R4, etc.; R4 = H, alkyl, alkenyl, etc.; m = 0-4; n = 0-4] and their pharmaceutically acceptable salts, are prepared and disclosed as antiinflammatory agents. Thus, e.g., II was prepared by alkylation of amine III (preparation given) with 3-bromo-1,1,1-trifluoro-2-propanol. The activity of I was evaluated using surface binding studies and fluorescence polarization (no data). I should prove useful as antiinflammatory agents. Pharmaceutical compns. comprising I are disclosed.

ACCESSION NUMBER: 2005-588915 HCAPLUS

DOCUMENT NUMBER: 143197346

TITLE: Preparation of halogenated biaryl oxazolidinones as antiinflammatory agents

INVENTOR(S): Chen, Shili; Zhou, Jiacheng; Wu, Yunsheng; Wang, Depling; Salvino, Joseph M.; Oyleere, Adegboyega K.; Lou, Rongliang

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA; Bhattacharjee, Ashoke; Chen, Yi

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061468	A1	20050707	WO 2004-US39988	20041201
WO 2005061468	C1	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TU, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, IO, ZA, ZM, ZW				
RU: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


US 2005133971 A1 20050714 US 2004-1446 20041201
 PRIORITY APPLN. INFO.: US 2003-530371P P 20031217
 US 2004-576267P P 20040602

OTHER SOURCE(S): MARPAT 143197346
 IT 856907-45-4P 856907-45-2P 856907-01-8P
 856907-85-2P 856907-86-3P 856907-87-4P
 856907-88-5P 856907-89-6P 856907-92-1P
 856907-97-6P 856907-98-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of halogenated biaryl oxazolidinones as antiinflammatory

L12 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


agents)
 RN 856907-04-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-(fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-43-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-(fluoropropyl)amino]methyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 856907-01-8 HCAPLUS


L12 ANSWER 3 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-methyl-1H-1,2,3-triazol-1-ylmethyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856907-85-2 HCAPIUS
 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[(4-hydroxymethyl)-1H-1,2,3-triazol-1-ylmethyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 3 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 856907-88-5 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[(5-hydroxymethyl)-4-methyl-1H-1,2,3-triazol-1-ylmethyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-89-6 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4,5-bis(methoxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856907-92-1 HCAPIUS
 CN Acetamide, N-[1-[(SR)-3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-ylmethyl]-, (9CI) (CA INDEX NAME)

Page 3929/11/2005


L12 ANSWER 3 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 856907-86-3 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[(5-hydroxymethyl)-1H-1,2,3-triazol-1-ylmethyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856907-87-4 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-5-[(4-hydroxymethyl)-5-methyl-1H-1,2,3-triazol-1-ylmethyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 3 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 856907-97-6 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856907-98-7 HCAPIUS
 CN 2-Oxazolidinone, 5-[(5-[(ethylthio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-3-[2-fluoro-4'-[[3-fluoropropyl]amino]methyl][1,1'-biphenyl]-4-yl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-95-3P 847490-64-6P 847490-65-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of halogenated biaryl oxazolidinones as antiinflammatory agents)


RN 501939-95-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847490-64-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847490-65-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. I [X = C, N; R1-1' = H, F; R2 = amino, alkoxy, triazolyl, etc.; R3-4 = H, alkyl, etc.; Het = heterocyclic ring, heteroarom. ring, etc.] are prepared. For instance, (R)-3-[4-(2-methyltetrazol-5-yl)pyridin-5-yl]-3-fluorophenyl]-5-hydroxymethyloxazolidin-2-one (II) is prepared from 2-(2-methyltetrazol-5-yl)-5-bromopyridine and (R)-3-(4-triptylstananyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol (preparation given). II exhibits MIC₅₀ = 0.5 µg/mL against MRSA and 0.25 µg/mL against VRE. I show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The amino acid or phosphate prodrugs of the invention show good water solubility. Further, the derivs. of the present invention may exert potent antibacterial activity vs. various human and animal pathogens, including Gram-pos. bacteria such as *Staphylococci*, *Enterococci* and *Streptococci*, anaerobic microorganisms such as *Bacteroides* and *Clostridia*, and acid-resistant microorganisms such as *Mycobacterium tuberculosis* and *Mycobacterium avium*.

ACCESSION NUMBER: 2005:564663 HCAPLUS

DOCUMENT NUMBER: 143197343

TITLE: Preparation of oxazolidinone broad-spectrum antibiotics

INVENTOR(S): Rhee, Jae Keol; Im, Weon Bin; Cho, Chong Ewang; Choi, Sung Hak; Lee, Tae Ho

PATENT ASSIGNEE(S): Dong-A Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 65 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200505886	A1	20050630	WO 2004-KR3327	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NX, HZ, NA, NL, NO, NZ, OM, PG, PE, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, TU, ZA, ZM, ZW				
NW: DE, DO, GA, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UC, BH, ZW, AM, AZ, BV, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CV, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, OM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: KR 2003-93342 A 20031218

KR 2004-58809 A 20040727

OTHER SOURCE(S): MARPAT 143:97343


IT 700370-32-7P 831201-38-8P 856866-76-7P

856866-77-8P 856867-06-5P 856867-08-8P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRE)


RN 700370-32-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(2-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-38-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856866-76-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-(5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856866-77-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[6-(1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856867-06-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(4-(hydroxymethyl)-2-thiazolyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 856867-07-7 HCAPLUS
 CN Glycine, [2-(2'-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of oxazolidinone broad-spectrum antibiotics effective against MRSA and VRB)

RN 856867-07-7 HCAPLUS
 CN Glycine, [2-(2'-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 856867-08-8 HCAPLUS
 CN Glycine, [2-(2'-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-4-thiazolyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 856867-07-7
 CHF C24 H21 F6 O4 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CHF C2 H F3 O2



IT 856867-07-7

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 17 Jun 2005
 GI



AB The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivs. (shown as I) variables defined below, e.g. (S)-N-[3-(4-(4-cyanoethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl)-2-oxomazolidin-5-yl]methyl)ethanamide (shown as II), processes for making compds. as well as antimicrobial compns containing said derivs. as active ingredients and methods of treating bacterial infections with the said derivs. MIC (µg/ml) and/or ED50 (µg/kg) values are tabulated for 3 species of bacteria. For I: m = 0-3; n = 1-3; X = CN, -OH, or hydrogen; Y = H (with the proviso that when Y is H, X is OH, F or CN); (un)substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heterocyclic amino, heterocyclycetononyl, cyano, halogen, (un)substituted carboxylic ring or heterocyclic ring containing a hetero atom = O or S or X and Y together form an (un)substituted, (un)saturated or 3-membered heterocyclic ring having 1-4 hetero atoms = H, O or S or includes the S atom of groups like sulfinyl or sulfonyl as a part of heterocyclic ring or X and Y together form O; A, B = H, C1-C6 alkyl or halogen; R2, R3 = H or halogen; R4 = C1-C6 alkylsulfonyl, alkylsulfonyloxyacetamide, (un)substituted aminosulfonyl, aminosulfonyloxy, aminosulfonyl, (un)substituted amino, azido, aminonitrile, isocyanato, formamido, (un)substituted M-hydroxyformamido, substituted C1-C6 alkylcyano, (un)substituted C1-C6 alkylamido, (un)substituted C1-C6 alkylthiocarbonylamido, (un)substituted alkylcarbamato, (un)substituted ureido, (un)substituted five to six membered heterocyclic ring, (un)substituted five to six membered heterocyclic ring, (un)substituted heteroaryloxy, (un)substituted heteroaryl, or a mercapto substituted by C1-C6 alkyl group; addnl. details including provisos are given in the claims. Methods of preparation are claimed and approx. 180 example preps. are included. For example, S1 & II was prepared by reacting (S)-N-[3-(4-(1-oxa-6-azaspiro[2.5]octan-6-yl)-3-fluorophenyl)-2-oxomazolidin-5-yl]methyl)ethanamide with KCN in MeOH/DMF (1:5) at 25° for 14 h.

ACCESSION NUMBER: 2005523447 HCAPLUS

DOCUMENT NUMBER: 14315964

TITLE: Preparation of 3-(4-piperidinophenyl)oxazolidinones


L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 having antibacterial activity with improved in vivo efficacy
 INVENTOR(S): Deshpande, Prasad Keshav; Sindkhedkar, Milind Dattatraya; Phansalkar, Mahesh Shiriram; Yeole, Ravinda Dattatraya; Gupte, Shrikant Vinayak; Chugh, Yati; Shetty, Nitin; Bhagwat, Sachin Subhash; De Souza, Noel John; Patel, Mahesh Vithalbhai
 PATENT ASSIGNEE(S): India
 SOURCE: PCT Int. Appl., 167 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054234	A2	20050616	WO 2004-IN276	20040908
WO 2005054234	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GB, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005143421 AI 20050630 US 2004-935708 20040907
 OTHER APPLN. INFO.: IN 2003-MU924 A 20030908
 OTHER SOURCE(S): MARPAT 143:59964

IT 853797-09-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)
 RN 853797-09-8 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5R)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 853797-08-7 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-10-1 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl] -, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-11-2 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxamide, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 having antibacterial activity with improved in vivo efficacy
 INVENTOR(S): Deshpande, Prasad Keshav; Sindkhedkar, Milind Dattatraya; Phansalkar, Mahesh Shiriram; Yeole, Ravinda Dattatraya; Gupte, Shrikant Vinayak; Chugh, Yati; Shetty, Nitin; Bhagwat, Sachin Subhash; De Souza, Noel John; Patel, Mahesh Vithalbhai
 PATENT ASSIGNEE(S): India
 SOURCE: PCT Int. Appl., 167 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

IT 853797-11-2P, (S)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-4-carboethoxy-1,2,3-triazole
 853797-06-8P, (S)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-4-aminocarbonyl-1,2,3-triazole
 853797-08-7P, (S)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-4-cyano-1,2,3-triazole
 853797-10-1P, (S)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-4-carboethoxy-1,2,3-triazole
 853797-11-2P, (S)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-carboethoxy-1,2,3-triazole
 853797-06-4P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-aminocarbonyl-1,2,3-triazole
 853797-48-5P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-cyano-1,2,3-triazole
 853797-45-2P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-4-cyano-1,2,3-triazole
 853797-46-3P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-carboethoxy-1,2,3-triazole
 853797-47-4P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-aminocarbonyl-1,2,3-triazole
 853797-48-5P, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-5-cyano-1,2,3-triazole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)

RN 853797-04-3 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl] -, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-06-5 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 853797-12-3 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-45-2 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-46-3 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[(5S)-3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl] -, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853797-47-4 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxamide, 1-[(5R)-3-(4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853797-48-5 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carbonitrile, 1-[(5R)-3-(4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 853797-07-6, (R)-1-[(3-[4-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl)-4-carboethoxy-1,2,3-triazole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)
 RN 853797-07-6 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-(4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinylmethyl]-,

ED Entered STN: 01 Jun 2005

AB A new series of N-linked 5-triazolylmethyl oxazolidinones with varying substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates. Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms. One of the compds. showed enhanced antibacterial activity against *Moraxella catarrhalis*.

ACCESSION NUMBER: 2005:465012 HCAPLUS

DOCUMENT NUMBER: 143149749

TITLE: Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones

AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait

SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(12), 4113-4123

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 371195-29-8P

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)

RN 371195-29-8 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-41-3P 859445-42-4P 859445-43-5P
 859445-44-6P 859445-45-7P 859445-46-8P
 859445-47-9P 859445-48-0P 859445-49-1P
 859445-50-4P 859445-51-5P 859445-52-6P
 859445-53-7P 859445-54-8P 859445-55-9P
 859445-56-0P

Absolute stereochemistry.




L12 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)

RN 859445-41-3 HCAPLUS


CN 1-Piperazinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-42-4 HCAPLUS
 CN Piperazine, 1-acetyl-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-43-5 HCAPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-44-6 HCAPLUS

CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(trichloroacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-45-7 HCAPLUS

CN Piperazine, 1-(dichloroacetyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-46-8 HCAPLUS

CN 1-Piperazinecarboxhioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-47-9 HCAPLUS

CN Piperazine, 1-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-48-0 HCAPLUS

CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-49-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-50-4 HCAPLUS

CN 1-Piperazinecarboxhioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-51-5 HCAPLUS


CN Piperazine, 1-(1,2-dioxopropyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-52-6 HCAPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(2-methyl-1-oxopropyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-53-7 HCAPLUS
 CN Piperazine, 1-(cyclopentylcarbonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 859445-55-9 HCAPLUS
 CN Piperazine, 1-benzoyl-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-56-0 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 859445-40-2P
 RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl




RN 859445-54-8 HCAPLUS
 CN Piperazine, 1-(cyclohexylcarbonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 859445-40-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 371195-30-1
 CHF C16 H19 F N6 O2

Absolute stereochemistry.



CH 2

CRN 76-05-1
 CHF C2 H F3 O2






REFERENCE COUNT:

28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 13 May 2005
 GI



AB The invention relates to a preparation of novel oxazolidinone derivs. of formula I (R is H, amide, aldehyde, or nitrile, etc.; each X is independently N or CH), useful as antibacterial agents. For instance, oxazolidinone derivative II (MIC (μg/ml): str. pyogenes 77A - 0.4, s. aureus 285 - 0.8, MRSA 2 - 1.6; LD50 >5000 mg/kg) was prepared via 1,3-dipolar cycloaddn. of vinyl acetate to (azidomethyl)oxazolidinone derivative III with a yield of 74%.

ACCESSION NUMBER: 2005409511 HCAPLUS

DOCUMENT NUMBER: 142463731

TITLE: A preparation of novel oxazolidinone derivatives, useful as antibacterial agents

INVENTOR(S): Kang, Jae-Hoon; Park, Chun-Ho; Kwon, Jin-Sun

PATENT ASSIGNEE(S): Il-Dong Phara. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042523	A1	20050512	WO 2004-KR2805	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, NO,				


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Double bond geometry unknown.



RN 851529-83-4 HCAPLUS

CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851529-97-0 HCAPLUS

CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-98-1 HCAPLUS

CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SX, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CN, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: KR 2003-77372 A 20031103
 KR 2004-82328 A 20041014

OTHER SOURCE(S): MARPAT 142:463731

IT 851529-76-5P 851529-81-2P 851529-82-3P

851529-97-0P 851529-98-1P


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-76-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851529-81-2 HCAPLUS

CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851529-82-3 HCAPLUS

CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 3-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 851530-02-4P


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851530-02-4 HCAPLUS

CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-77-6P 851529-96-9P 851530-00-2P

851530-01-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-77-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 851529-96-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-00-2 HCAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851530-01-3 HCAPLUS
 CN 1H-Pyrazole-4-carboxamide, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 851529-78-7P 851529-85-6P 851529-86-7P
 851529-87-8P 851529-88-9P 851529-89-0P
 851529-90-3P 851529-91-4P 851529-92-5P
 851529-93-6P 851529-94-7P 851529-95-8P
 851529-99-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel oxazolidinone derivs. useful as antibacterial agents)
 RN 851529-78-7 HCAPLUS
 CN Carboxamic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851529-85-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1H-1,2,3-triazol-1-yl)-3-oxazolidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued) .




RN 851529-86-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2H-tetrazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-87-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 851529-88-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1H-pyrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 851529-89-0 HCAPLUS
 CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 851529-90-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1-pyrrolidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 851529-76-5
 CMF C16 H18 F N5 O2

Absolute stereochemistry.



CM 2


CRN 7664-93-9
CMF H2 O4 S

RN 851529-91-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851529-77-6
CMF C16 H14 F N5 O2

Absolute stereochemistry.




CM 2

CRN 7664-93-9
CMF H2 O4 S

RN 851529-92-5 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

Absolute stereochemistry.



CM 2


CRN 7664-93-9
CMF H2 O4 S

RN 851529-93-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 851529-76-5
CMF C16 H18 F N5 O2

Absolute stereochemistry.



CM 2




RN 851529-94-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-pyrrrol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 851529-77-6
CMF C16 H14 F N5 O2

Absolute stereochemistry.



CM 2


CRN 77-92-9
CMF C6 H8 O7

RN 851529-95-8 HCAPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 851529-83-4
CMF C17 H13 F N6 O2

Absolute stereochemistry.




CM 2

CRN 77-92-9
CMF C6 H8 O7


RN 851529-99-2 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 851529-80-1P 851529-84-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent);
(preparation of novel oxazolidinone derivs. useful as antibacterial agents)
RN 851529-80-1 HCAPLUS
CN 2-Oxazolidinone, 3-(4-amino-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 851529-84-5 HCAPLUS
CN 2-Oxazolidinone, 3-(4-azido-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. represented by the formula I [wherein A = isoxazolin-3,5-diyil, 2-oxazolinone-3,5-diyil, 2-furanone-3,5-diyil, 5-isoxazolinone-2,4-diyil] X = N or Cr, Z = oxy-isoxazolyl, (oxy)-1,2,3-triazolyl, aminocarbonylmethyl, etc.; R2-R5 = independently H, Cl, F, Me, NH2, or OH; L, Y = independently H, OH, F, O, NO2, alkyl, m, n, p = independently 0 or 1, and pharmaceutically acceptable salts thereof] were prepared as antimicrobial agents. For example, II was given in a multi-step synthesis starting from the reaction of 1,2,3,6-tetrahydropyridine with 3,4-difluorobenzene. I were tested for inhibition against SAUR 9213, SPNE 9912, HINF 30063 and MC 30603 with MIC values of 0.25-64 μ g/ml. Thus, I and their pharmaceutical compds. are useful as antibacterial agents for the treatment of a gram-neg. microbial infection.

ACCESSION NUMBER: 20051182660 HCAPLUS
DOCUMENT NUMBER: 142:280197
TITLE: Preparation of aryloxazolidinone derivatives as antimicrobial agents
INVENTOR(S): Gordiev, Mikhail; Wang, Qiang
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019214	A1	20050303	WO 2004-1B2669	20040813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PE, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

L12 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RW: BW, GH, GR, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005065187 A1 20050324 US 2004-924752 20040824
PRIORITY APPLN. INFO.: US 2003-497531P P 20030825
OTHER SOURCE(S): MARPAT 142:280197
IT 847256-81-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of aryloxazolidinone derivs. as antimicrobial agents)

RN 847256-81-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[(3S,4R)-3,4-dihydro-1-piperidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 847256-92-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of aryloxazolidinone derivs. as antimicrobial agents)

RN 847256-92-0 HCAPLUS
CN 4-Piperidinone, 1-[2-fluoro-4-[(SR)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 847257-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of aryloxazolidinone derivs. as antimicrobial agents)

RN 847257-18-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1(2H)-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 04 Mar 2005
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A and B independently = Ph, pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl; R1 and R2 = independently = halo, CF₃, CN, NO₂, NR₂, COR₂, etc.; R3 = OR₄, NR₂, COR₂, CO₂R₄, etc.; R₄ independently = H, (un)substituted-alkenyl, -alkynyl, -acyl, etc.]; M = (un)substituted, (un)saturated carbocycle or aryl heterocycle containing one or more heteroatoms chosen from N, O, and S; L = X, L₁, L₂, L₁X₂, L₁X₂X₃, Y₂, L₁X₂, X₁X₂X₃ wherein X independently = O, NR₄, NO₂(OR₄), NR₄NR₄, etc., and L₁ and L₂ are independently (un)substituted-alkenyl, -alkynyl, -acyl, m = 0-4, n = 0-4], and their pharmaceutically acceptable salts, are prepared. Thus, e.g., II was prepared by conversion of TBDDPS protected 1-bromo-4-(2-hydroxyethyl)benzenes to the arylboronic acid which is coupled with N-[3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl]acetamide followed by desilylation, mesylation, and substitution with imidazole. I are disclosed as potential anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents (no data). More particularly, the invention relates to a family of compds. having both a biaryl moiety and at least one heterocyclic moiety that are useful as such agents.

ACCESSION NUMBER: 2005182657 HCAPIUS

DOCUMENT NUMBER: 142280195

TITLE: Preparation of biaryl heterocyclic compounds and methods of making and using the same in pharmaceutical applications

INVENTOR(S): Zhou, Jiacheng; Bhattacharjee, Ashoke; Chen, Shili; Chen, Yit; Farmer, Jay J.; Goldberg, Joel A.; Hamelmann, Roger; Lou, Rongliang; Orbin, Alia; Oyejide, Adeboyeja X.; Salvino, Joseph M.; Springer, Diane M.; Tran, Jennifer; Wang, Deping; Wu, Yusheng

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 259 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019211	A2	20050303	WO 2004-US17101	20040602
W: AM, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KB, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GE, GM, KZ, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L12 ANSWER 9 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 US 2005203147 A1 20050915
 PRIORITY APPLN. INFO.:
 US 2005-118808 P 20050429
 US 2003-475430P P 20030603
 US 2003-475453P P 20030603
 US 2003-490855P P 20030729
 US 2003-529731P P 20031215
 US 2003-531594P P 20031219
 US 2004-859476 A1 20040602


OTHER SOURCE(S): MARPAT 142:280195
 IT 847499-40-1P 847490-40-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)
 RN 847499-40-1 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-imidazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847490-40-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-1,2,3-triazol-1-ylmethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 9 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 IT 501939-95-3P 847490-64-6P 847490-65-7P
 RL: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of biaryl heterocyclic compound as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents)
 RN 501939-95-3 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847490-64-6 HCAPIUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 847490-65-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[4'-(chloromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 9 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




L12 ANSWER 10 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 21 Jan 2005
 GI




AB New oxazolidinones having a cyclopropyl moiety (I) [R1, R2 = independently H, NR5R6, CR7R8R9, C(R)2R10, C2H2NR11, C(O)R12, C(:N)H]H, C(:N)R13]H, C(:NR13)R13, C(O)N(R13)2, C(:N)H]N(R13)2, C(:N)H]C(:X1)N(R13)2, C(:N)H]R7, N(R13)C(:X1)N(R13)2, C2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyano-C1-6 alkyl, cyano, CH:C(R)2, etc.; A = C, CH; N - represents an optional bond; ring A = aryl, heteroaryl, heterocyclic; R1 = H, Cl-6 alkyl, R3 = (un)substituted aromatic heterocyclic group containing at least one nitrogen in the ring which is attached through a bond on any N; R4 = H, halogen, Cl-6 alkyl; R5 = 1-3, provided that R5 is not R5, R6 = H, each (un)substituted Cl-6 alkyl, Cl-6 acyl, or Cl-6 alkoxyl; R7 = H, halo, cyano, CO2R, CON(R)2, CHO, CH2NHAc, C(:N)R, OH, Cl-6 alkyl, Cl-6 alkyl, alkenyl, (CH2)nNH2, etc.; R8, R9 = H, cyano, each (un)substituted Cl-6 alkyl or Ph; X1 = O, S, NR13, NCR2R14, or NSO2R14; R13 = H, Cl-6 alkyl, C6-10 aryl, NR5R6, SR8, S(O)2R8, cyano, OH, Cl-6 alkoxycarbonyl, CO2R, etc.; R14 = amino, Cl-6 alkyl, Cl-6 haloalkyl, (un)substituted Ph, etc.; R15 = Cl-6 alkyl or (un)substituted benzyl; m, n, p, q = 0, 1]; enantiomers, diastereomers, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof are prepared. These compds. are effective as antibacterial agents against aerobic and anaerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, *Bacteroides* sp., *Clostridium* sp., as well as acid-fast organisms such as *Mycobacterium tuberculosis* and other mycobacterial species. They are coadministered with vitamin B2, vitamin B4, vitamin B12, or folic acid to prevent or treat oxazolidinone-associated side effect such as normocytic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, chelosis,

L12 ANSWER 10 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.




RN 828915-22-6 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-23-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-(hydroxymethyl)bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-24-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxymethyl)bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 10 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis. Thus, (R)-5-azidomethyl-3-[4-[(1a,5a,6a)-6-(tert-butoxycarbonylamo)3-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]oxazolidin-2-one [370 mg] and 2,5-norbornadiene (891 mg) in dioxane (65 ml) was heated at 70° for 6 h, and then concd. in vacuo. A suspension of the residue in diethylene glycol di-Me ether (18.5 ml) was heated at 140° for 10 min to give 1-[5(R)-3-[4-azabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxazolidin-5-ylmethyl]-1,2,3-triazole which was treated with 12 N HCl/MeOH at room temp. for 10.5 h to give, after workup, compds. (II) (X = H), II (X = F) showed min. inhibitory concn. of 0.25, 0.25, 1, 1 μ g/ml against methicillin-resistant *Staphylococcus aureus*, penicillin- and quinolone-resistant *S. pneumoniae*, *S. pyogenes* IID692, vancomycin- and quinolone-resistant *Enterococcus faecium*, and *Moraxella catarrhalis* ATCC25238, resp.


ACCESSION NUMBER: 2005:58200 HCAPIUS
 DOCUMENT NUMBER: 142:155957
 TITLE: Preparation of 3-aryloxazolidin-2-one derivatives as antibiotics
 INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 43 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200505422	A1	20050120	WO 2004-A20738	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BW, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MH, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PE, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TH, TR, TT, TZ, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, BY, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BU, CY, CG, CI, CH, GA, GN, GQ, GW, ML, MA, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-483901P P 20030702
 US 2004-546985P P 20040224


OTHER SOURCE(S): MARPAT 142:155957
 IT 828915-21-SP 828915-22-SP 828915-23-7P
 828915-24-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of arylloxazolidin-2-one derivs. as antibacterial agents)
 RN 828915-21-5 HCAPIUS
 CW 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




IT 828915-93-3P 828915-94-4P 828915-25-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of arylloxazolidin-2-one derivs. as antibacterial agents)
 RN 828915-93-3 HCAPIUS
 CW 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-94-4 HCAPIUS
 CW 2-Oxazolidinone, 3-[4-[6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]bicyclo[3.1.0]hex-2-en-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 828915-25-9 HCAPIUS


L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828915-26-0 HCAPLUS
 CN Bicyclo[3.1.0]hex-2-ene-6-carbonitrile, 3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-70-4P 501939-95-3P 828252-99-9P
 828253-00-5P 828915-27-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); PREP (Preparation); RACT (Reactant or reagent); (preparation of arylomazolidin-2-one derivs. as antibacterial agents)
 RN 501939-70-4 HCAPLUS
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 828253-00-5 HCAPLUS
 CN Carbamic acid, [(1a,5a,6a)-3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 828915-27-1 HCAPLUS
 CN Bicyclo[3.1.0]hex-2-ene-6-carboxaldehyde, 3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501939-95-3 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828252-99-9 HCAPLUS
 CN Carbamic acid, [(1a,5a,6a)-3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 21 Jan 2005
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB: Oxazolidinones I and II [wherein R1, R2 = independently H, NH2, CH3 and derivs., CHO and derivs., CONH2 and derivs., SO2H and derivs., (un)substituted heterocyclic, etc., Y, Z = (un)substituted arylene, heteroarylene; R1a = defined as R1 less H, Y = O, H, OH, or halo; A = C or N with provisos; R4 = H, alkyl; R5 = NHCO(O)H and derivs., NHSO2H and derivs., (un)substituted NH-heteroaryl, etc.; B = (CH2)n; n = 0-1; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant *Staphylococci*, *Streptococci* and *Enterococci*, *Bacteroides*, *Clostridia*, as well as acid-fast organisms such as *Mycobacterium tuberculosis*, and other mycobacterial species. Thus, reacting N-[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxoazolidin-5-ylmethyl]acetamide with bis(pinacolato)diboron, and rd-coupling with 5-bromo-2-(1-cyanocyclopropen-1-yl)pyridine gave oxazolidinone III. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Enterococcus faecium*. III inhibited *Staphylococcus aureus* *in vitro* with a min. inhibitory concentration of 0.06 µg/mL.

ACCESSION NUMBER: 2005158190 HCAPLUS
 DOCUMENT NUMBER: 142:155938
 TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics
 INVENTOR(S): Fukuda, Yasumichi
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005420	A1	20050120	WO 2004-US20737	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CL, CU, CO, CR, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LN, LS, LT, LV, MD, MG, MK, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, US, UZ, VC, VN, YU, ZA, ZH, ZW, AZ, BY, KG, LS, MG, MZ, NA, SD, SL, ST, TZ, UG, ZM, ZV, AM, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-483904P	P 20030702
			US 2004-546980P	P 20040224


OTHER SOURCE(S): MARPAT 142:155938
 IT 827627-78-0P 827627-91-0P 827627-98-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (antibacterial agent; preparation of cyclopropyl-oxazolidinones as

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 antibiotics)

RN 827627-75-8 HCAPLUS

CN Carbamic acid, [(1a,5a,6a)-3-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-91-8 HCAPLUS

CN Carbamic acid, [(1a,5a,6a)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-98-5 HCAPLUS

CN Carbamic acid, [1-[5-[2-fluoro-4-[(5R)-5-[4-methyl-1H-1,2,3-triazol-1-yl]methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]cyclopropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-77-0 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(6-(1-aminocyclopropyl)-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-78-1 HCAPLUS

CN Cyclopropanecarbonitrile, 1-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827627-76-9P 827627-77-0P 827627-78-1P

827627-79-2P 827627-92-9P 827627-97-4P

827627-99-6P 827628-11-5P 827628-12-6P

827628-13-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); PROPS (Properties); ANT (Antibacterial agent); preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 827627-76-9 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(6-(1-aminocyclopropyl)-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 827627-79-2 HCAPLUS

CN Cyclopropanecarbonitrile, 1-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827627-92-9 HCAPLUS


CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-97-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6a)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827627-99-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1-aminocyclopropyl)-3-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-11-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-12-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1-aminocyclopropyl)-5-fluoro-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827628-13-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1-aminocyclopropyl)-3-pyridinyl]-3,5-difluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-70-4P 501939-98-3P 827628-21-7P
 827628-30-8P 827628-34-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)


RN 501939-70-4 HCAPLUS
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-95-3 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-21-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827628-30-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, (9CI) (CA INDEX NAME)


L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.RN 827628-34-2 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 700370-33-8 827628-35-3
RL: RCT (Reactant); PACT (Reactant or reagent)
(preparation of cyclopropyl-oxazolidinones as antibiotics)
RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dicarbaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 827628-35-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3,5-difluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jan 2005
GI

AB Title compds. [I; R1 = H, NR5R6, CR7R8R9, COR13, (substituted) heterocyclic, etc.; A = NR, O, S, SO2; Ar = (substituted) acyl, heteroacyl, heterocyclic; R3 = NR13(C1X2)R12, NR13SO2R14, (substituted) heteroaryl, etc.; n = 0, 1; Rm = H, alky1; R5, R6 = H, (substituted) alkyl, acyl, heteroacyl, etc.; R5R6, R7R8 = atoms to form a 3-7 membered heterocyclic ring; R7 = H, halo, cyano, CHO, OH, alkyl, alkoxy, alkenyl, etc.; R8, R9 = H, cyano, (substituted) alkyl, Ph; R13 = H, alkyl, acyl, NR5R6, cyano, OH, alkylcarbonyl, CO2H, acyl, (substituted) (heterocyclic) ring, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocyclic, Ph; X2 = O, S, NH, NSO2R14], were prepared. Thus, 1-benzoyloxycarbonylamino-4-[(1a,5a,6B)-6-cyanobicyclo[3.1.0]hexan-6-yl]benzene in THF at -78° was treated with BuLi and then with (R)-cyclydil butyrate followed by stirring for 2 h gave 5(R)-3-(4-[(1a,5a,6B)-6-cyanobicyclo[3.1.0]hexan-6-yl]phenyl)-5-hydroxymethyloxazolidin-2-one. The latter was stirred 15 min. with Et3N and MeSO2Cl in CH2Cl2 at 0° to give a residue which was stirred at 70° with NaN3 in DMF to give 5(R)-azidomethyl-3-[4-[(1a,5a,6B)-6-cyanobicyclo[3.1.0]hexan-6-yl]phenyl]oxazolidin-2-one. The latter was hydrogenated in THF/MeOH over Lindlar catalyst to give 5(R)-aminomethyl-3-[4-[(1a,5a,6B)-6-cyanobicyclo[3.1.0]hexan-6-yl]phenyl]oxazolidin-2-one. This was stirred with Et3N and Ac2O in THF at 0° room temperature to give N-(5(S)-3-(4-[(1a,5a,6B)-6-cyanobicyclo[3.1.0]hexan-6-yl]phenyl)oxazolidin-5-ylmethyl)acetamide. The latter showed a minimum inhibitory concentration of 0.25 µg/mL against *Staphylococcus Aureus* Smith.

ACCESSION NUMBER: 2005:55213 HCAPLUS

DOCUMENT NUMBER: 1421:134582

TITLE: Preparation of oxazolidinone antibacterials

INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 58 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200505399	A1	20050120	WO 2004-US20736	20040629
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

L12 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-483905P P 20030702

US 2004-546947P P 20040224

US 2004-533963P P 20040318

OTHER SOURCE(S): MARPAT 142:134582

IT 827014-72-2P 827014-75-5P 827014-76-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)

(claimed compound) preparation of oxazolidinone antibacterials

RN 827014-72-2 HCAPLUS

CN Bicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827014-75-5 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827014-76-6 HCAPLUS


CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1a,5a,6B)-

Absolute stereochemistry.



RN 827015-45-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

OTHER SOURCE(S): MARMAT 142:155937


IT 831201-06-0P 831201-09-2P 831201-09-3P
 831201-14-0P 831201-16-2P 831201-20-6P
 831201-34-4P 831201-40-2P 831201-52-5P
 831201-54-5P 831201-56-6P 831201-57-0P
 831201-66-5P 831201-68-9P 831201-92-4P
 831201-96-9P 831201-98-0P 831202-08-5P
 831202-09-3P 831202-14-1P 831202-28-0P
 831202-30-3P 831202-44-1P 831202-54-1P
 831202-55-2P 831202-56-3P 831202-58-5P
 831202-61-0P 831202-68-4P 831202-67-0P
 831202-69-8P 831202-73-2P 831202-73-4P
 831202-74-5P 831202-78-0P 831202-78-9P
 831222-09-3P 831222-09-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BICL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antibacterial agent; preparation of cyclopropyl oxazolidinones as antibiotics)

RN 831201-06-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[3-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-08-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones I and II (wherein R1 = H, CH3 and derivs., CHO and derivs., CN, (un)substituted heterocycls; Y = NH and derivs., O, CN, S, SO, SO2; A, B = (un)substituted arylene, heteroarylene, heterocyclylene, etc.; D = (CH2)n; n = 0-1; R3 = H and derivs., aryl, NRC(X)2H and derivs.; R = H, alkyl; X2 = O, S, NH, etc.; Z = substituted aromatic heterocyclic group containing 1 to 4 nitrogens and at least one double bond; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs) are effective against aerobic and anaerobic pathogens such as multi-resistant *Staphylococci*, *Streptococci* and *Enterococci*, *Bacteroides*, *Clostridia*, as well as acid-fast organisms such as *Mycobacterium tuberculosis*, and other mycobacterial species. Thus, II+HCl was prepared by reacting N-(5(S)-3-(4-iodophenyl)-2-oxazolidin-5-ylmethyl)acetamide (preparation given) with bis(pinacolato)diboron, Pd-coupling with 5-bromo-2-[(1a,5a,6b)-3-tert-butyloxycarbonyl-6-cyano-3-azabicyclo[3.1.0]hexan-6-yl]pyridine (preparation given), and BOC-deprotection. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Enterococcus faecium*. II inhibited *Staphylococcus aureus* Smith *in vitro* with a min. inhibitory concentration of 0.125 µg/mL.

ACCESSION NUMBER: 200555212 HCAPLUS

DOCUMENT NUMBER: 142:155937

TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics

INVENTOR(S): Fukuda, Yasumichi

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIIXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005398	A2	20050120	WO 2004-US20734	20040629
WO 2005005398	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SK, SG, SX, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BM, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SK, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038092	A1	20050217	US 2004-878637	20040629




RN 831201-09-3 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-14-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-16-2 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-28-6 HCAPIUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-52-6 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-54-8 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2'-fluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-34-4 HCAPIUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-40-2 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,5-trifluoro-4'-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-56-0 HCAPIUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-64-0 HCAPIUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831201-86-6 HCPLUS
CN Carbamic acid, [1-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B


-OBu-t

RN 831201-88-8 HCPLUS



RN 831201-98-0 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(acetyloxy)acetyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-09-5 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 13 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(2-aminostyryl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-92-4 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[2-hydroxy-1-(hydroxymethyl)ethyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-96-8 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[(1,1-dimethylethoxy)carbonyl]amino]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-10-9 HCPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[5-[2-fluoro-4-[(5R)-5-(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-12-1 HCPLUS
CN 1-Piperazinecarboxylic acid, 4-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 831202-29-9 HCAPIUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-30-3 HCAPIUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 831202-55-2 HCAPIUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 3-(bromosacetyl)-6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-56-3 HCAPIUS
 CN Carbamic acid, [(1a,3b,5a,6b)-6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 831202-46-1 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-54-1 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-58-5 HCAPIUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



-OBu-t

RN 831202-61-0 HCAPIUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t


RN 831202-65-4 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-(5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl)-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

—OBu-t

RN 831202-67-6 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-(5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl)-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—OBu-t

—OBu-t

RN 831202-69-8 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-(5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl)-3-azabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



—OBu-t


RN 831202-71-2 HCAPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-73-4 HCAPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-74-5 HCAPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-75-6 HCAPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-78-9 HCPLUS
 CN Carbamic acid, [(1a,3b,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-09-3 HCPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

831202-17-6P 831202-18-7P 831202-19-8P
 831202-20-1P 831202-21-2P 831202-22-3P
 831202-23-4P 831202-24-5P 831202-27-8P
 831202-29-0P 831202-31-4P 831202-32-5P
 831202-33-6P 831202-34-7P 831202-37-0P
 831202-42-7P 831202-45-0P 831202-53-0P
 831202-57-4P 831202-59-6P 831202-63-2P
 831202-64-3P 831202-66-5P 831202-61-4P
 831203-07-7P 831221-99-9P 831222-02-7P
 831222-03-8P 831222-06-1P 831222-07-2P
 831222-10-7P 831222-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antibacterial agent; prepn. of cyclopropyl-oxazolidinones as antibiotics)

RN 831201-07-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[3-fluoro-4'-([(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-13-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-09-4 HCPLUS
 CN Carbamic acid, [(1a,5a,6b)-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 831201-07-1P 831201-13-9P 831201-15-1P
 831201-17-3P 831201-29-7P 831201-31-1P
 831201-35-5P 831201-37-7P 831201-39-8P
 831201-39-9P 831201-41-3P 831201-50-4P
 831201-51-5P 831201-53-7P 831201-55-9P
 831201-57-1P 831201-61-7P 831201-65-1P
 831201-84-4P 831201-85-5P 831201-87-7P
 831201-89-9P 831201-90-2P 831201-91-3P
 831201-93-5P 831201-94-6P 831201-95-7P
 831201-97-9P 831201-99-1P 831202-04-1P
 831202-05-2P 831202-06-3P 831202-07-4P
 831202-09-6P 831202-11-0P 831202-13-2P
 831202-14-3P 831202-15-4P 831202-16-5P



● HCl

RN 831201-15-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-17-3 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-29-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1 α ,5 α ,6 β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-31-1 HCAPLUS
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-38-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[5-fluoro-4-[(6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-39-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-35-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(6-[(1 α ,5 α ,6 β)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-37-7 HCAPLUS
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-41-3 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-50-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[2',3,6'-trifluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, 1,1-dimethyl ethyl ester, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-51-5 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,6'-trifluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-53-7 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-55-9 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-57-1 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-61-7 HCAPIUS
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-65-1 HCAPIUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-84-4 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-(2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-methyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-85-5 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-87-7 HCAPIUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-(2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-89-9 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[2-(4H-1,2,4-triazol-4-yl)ethyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-90-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-morpholinylacetyl)-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831201-91-3 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-(5-cyano-2-pyridinyl)-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831201-93-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-pyrrolidinylcarbonyl)-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-94-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[4-hydroxy-2-pyrrolidinyl]carbonyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-95-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[4-fluoro-2-pyrrolidinyl]carbonyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 831201-97-9 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6b)-6-amino-3-azabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, dihydrochloride, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831201-99-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(hydroxyacetyl)-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-04-1 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-cyano-6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-05-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-methyl-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-06-3 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6b)-6-(hydroxymethyl)-3-oxabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-07-4 HCPLUS
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-09-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

RN 831202-11-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

RN 831202-13-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-piperazinylacetyl)-, dihydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl


RN 831202-14-3 HCPLUS
 CN 3-Oxabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylethyl)-3-oxazolidinyl]phenyl]-2-thienyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-15-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-piperidinylacetyl)-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-16-5 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(1-pyrrolidinylacetyl)-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



● HCl

RN 831202-19-8 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-hydroxy-2-pyrrolidinylcarbonyl)-, monohydrochloride, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 831202-20-1 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-(4-fluoro-2-pyrrolidinylcarbonyl)-, (1 α ,5 α ,6 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-21-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1 α ,5 α ,6 β)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-22-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1 α ,5 α ,6 β)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 831202-23-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6B)-6-amino-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831202-24-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6B)-6-amino-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-27-8 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(4-methyl-1-piperazinyl)acetyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

→ Me

RN 831202-29-0 HCAPLUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-31-4 HCAPLUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, 3,3-dioxide, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 831202-32-5 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[2-(acetoxy)-1-[(acetoxy)methyl]ethyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 831202-33-6 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1S,3R,4S)-1-azabicyclo[2.2.1]hept-3-ylcarbonyl]-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 831202-34-7 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S)-2-methyl-3-oxiranemethyl]hexane-6-carbonitrile, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-37-0 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(1S,2S,3S)-1,2,3,4-thiatriazol-5-yl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-42-7 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3,5-trifluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-45-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2'-fluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-53-0 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[(1-aminocyclopropyl)carbonyl]-6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-57-4 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-59-6 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S,4R)-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-63-2 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-64-3 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-66-5 HCPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S)-2-pyrrolidinylcarbonyl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831202-81-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[2',3-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-07-7 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-[(2S,4S)-4-fluoro-2-pyrrolidinyl]carbonyl-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl


RN 831221-99-9 HCAPLUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-02-7 HCAPLUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-03-8 HCAPLUS
 CN 3-Thiabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxide, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-06-1 HCAPLUS
 CN Carbamic acid, [(1a,3a,5a,6b)-6-[5-(2-fluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethyl-1-ethoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-07-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831222-10-7 HCAPLUS
 CN Carbamic acid, [(1a,3a,5a,6b)-6-[5-[2,6-difluoro-4-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethyl-1-ethoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831222-11-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[(1a,5a,6b)-6-amino-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 831202-60-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)
 RN 831202-60-9 HCAPIUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[(1a,5a,6b)-6-cyano-6-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-3-oxabicyclo[3.1.0]hex-3-yl]carbonyl]-4-fluoro-, 1,1-dimethylethyl ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 700370-33-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-21-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827628-35-3 HCAPIUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-iodophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)



-OBu-t


IT 501939-70-4P 501939-95-3P 700370-33-8P
 827628-21-7P 827628-35-3P 831203-03-3P
 831203-04-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of cyclopropyl-oxazolidinones as antibiotics)
 RN 501939-70-4 HCAPIUS
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-95-3 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 831203-03-3 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-04-4 HCAPIUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 831202-93-8 831203-02-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of cyclopropyl-oxazolidinones as antibiotics)


L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 831202-93-8 HCAPLUS
 CN Methanesulfonic acid, trifluoro-, 2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 831203-02-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-, (1a,5a,6B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 831203-05-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyclopropyl-oxazolidinones as antibiotics)
 RN 831203-05-5 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 04 Jan 2005

AB Oxazolidinones represent a new and promising class of antibacterial agents. Current research in this area is mainly concentrated on improving the safety profile and the antibacterial spectrum. Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect. Recently, it was found that the 1,2,3-triazole is a good replacement for the conventional acetamide functionality found in oxazolidinones. The authors now disclose the finding that 1,2,3-triazoles bearing a substituent like Me, small substituted Me, bromo, or a linear (sp-hybridized) group at the 4 position are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A. The results are especially promising for the development of oxazolidinones with an improved safety profile. The MAO-A SAR can be rationalized on the basis of docking studies to a MAO-A/MAO-B homol. model.

ACCESSION NUMBER: 20053760 HCAPLUS

DOCUMENT NUMBER: 1421211423

TITLE: Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A

AUTHOR(S): Reck, Folkert; Zhou, Fei; Girardot, Marc; Kern, Gunther; Eyermann, Charles J.; Hales, Neil J.; Ramsay, Ron; R.; Gravestock, Michael B.

CORPORATE SOURCE: AstraZeneca Discovery, AstraZeneca R&D Boston,

Waltham, MA, 02451, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48 (2), 499-506

CODEN: JMCHAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 142:211423

IT 371195-02-7
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)


RN 371195-02-7 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 827628-34-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of cyclopropyl-oxazolidinones as antibiotics)
 RN 827628-34-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-iodophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


IT 591253-34-6P 591253-50-6P 591253-54-2P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation); RACT (Reactant or reagent)
 (Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)

RN 591253-34-8 HCAPLUS


CN Phosphoric acid, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-ylmethyl diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 591253-50-8 HCAPLUS
 RN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 14 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 591253-54-2 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4-(2,2-dibromoethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-95-1 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(trimethylsilyl)ethynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 591231-84-4P 591231-97-9P 591232-00-7P
 591253-26-8P 591253-36-0P 591253-60-0P
 591253-77-9P 591253-78-0P 591253-81-5P
 591253-82-6P 591253-94-0P 644493-91-0P

L12 ANSWER 14 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 844493-92-1P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation);
 (identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A)
 RN 591231-84-4 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(1-methylethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591231-97-9 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 14 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)

RN 591232-00-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-26-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 14 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)



Absolute stereochemistry.


RN 591253-36-0 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4-[(1E)-2-bromoethyl]-1H-1,2,3-triazol-1-yl)methyl]-3-(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 591253-77-9 HCPLUS
 CN 2-Oxazolidinone, 5-[(4-bromo-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-78-0 HCPLUS
 CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-81-5 HCPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-82-6 HCPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-94-0 HCPLUS
 CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 844493-91-0 HCPLUS
 CN 2-Oxazolidinone, 3-[(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 844493-92-1 HCPLUS
 CN 1H-1,2,3-triazole-4-carboxylic acid, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 21 Oct 2004
 GI



I



II

AB Title compds. I [A = oxazolyl, isoxazolyl, etc.; n = 0-1; Y = SOO-2, O, amino; Z = formyl, thiomethyl, acyl, etc.; W = CH2, CO, oximino, etc.; R1 = H, OH, amino, etc.; R2-3 = H, F; R4-5 = H, Cl, F, Me, NH2, OH; R6-7 = H, alkyl] are prepared. For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4 μ g/mL for S. aureus (UC9213). I are antibacterial agents.

ACCESSION NUMBER: 2004:872795 HCAPLUS

DOCUMENT NUMBER: 141:366217

TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials

INVENTOR(S): Renso, Adam Robert; Gordeev, Mikhail Fedor; Patel, Dinesh Vinoochhai; Gao, Hongwu; Josyula, Varu Prassad Venkata Nagendra

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, LLC, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: PIXXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089943	A1	20041021	WO 2004-1B1135	20040330
WO 2004089943	C1	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KK, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GR, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 thiabicyclo[3.1.0]hex-6-yl)-3,5-difluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



I

RN 777089-15-3 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



II

RN 777089-16-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



II

RN 777089-17-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Page 7429/11/2005

L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005192325 A1 20050901 US 2004-815589 20040401
 PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 141:366217
 IT 777088-83-2P 777089-13-1P 777089-14-2P
 777089-15-3P 777089-16-4P 777089-17-5P
 777089-18-6P 777089-23-3P 777089-24-4P
 780766-88-3P 780766-89-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)
 RN 777088-83-2 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



I

RN 777089-13-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



II

RN 777089-14-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-


L12 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.



I

RN 777089-15-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



II

RN 777089-16-4 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1S,5R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



II


RN 777089-17-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-98-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1e,5a,6b)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-99-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1e,5a,6b)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 777090-03-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. es



AB Title compds. [I; HET = pyrazolyl, imidazolyl, triazolyl, tetrazolyl; Q = (substituted) azolylphenyl, azolylpyridinyl, azolylloxazolyl, azolylthiazolyl, etc.], were prepared. Thus, (R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given), (PPh3)2PdCl2, and 5-triisopropylstannyl-3-methylisoxazole were heated together at 100°C in dioxane for 16 h to give title compound (II). II showed a min. inhibitory concentration of 1 µg/ml against *Staphylococcus aureus* MSQS (methicillin resistant and quinolone resistant).

ACCESSION NUMBER: 2004-799584 HCAPLUS

DOCUMENT NUMBER: 141:296028

TITLE: Preparation of azolylmethyloxazolidinones as antibiotics.

INVENTOR(S): Grevestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PXXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200403206	A1	20040316	WO 2004-GB1132	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KW, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, HK, MN, MV, HK, HZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZA, ZW				
EW: BG, GH, KE, LS, MW, MZ, SD, SI, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KE, MD, RU, TJ, TM, AT, BB, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, HL, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: MARPAT 141:296028	GB 2003-6357	A 20030320		
OTHER SOURCE(S): 765286-96-2P 765286-97-3P 765286-98-4P 765286-99-5P 765287-00-1P 765287-01-2P 765287-02-3P 765287-03-4P 765287-04-5P 765287-05-6P 765287-06-7P 765287-19-1P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 777090-03-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1e,5a,6b)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5A)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RN 765286-96-2 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765286-97-3 HCAPLUS

CN 3-Isoxazolecarboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-methylisoxazolyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765286-98-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3-hydroxymethyl)-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 765286-99-5 HCAPLUS


CN 2-Oxazolidinones, 3-[3-fluoro-4-[(4-phosphonoxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-00-1 HCPLUS
 CN 1H-Pyrazole-5-carbonitrile, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-01-2 HCPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-02-3 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-06-7 HCPLUS
 CN 2H-1,2,3-Triazole-2-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-18-1 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonoxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, disodium salt, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na


IT 501939-93-3P 765287-07-0P 765287-15-8P

765287-16-0P 765287-17-0P

RL: RCT (Reactant) SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolymethyloxazolidinones as antibiotics)


RN 501939-93-3 HCPLUS

CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-




RN 765287-03-4 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-04-5 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-05-6 HCPLUS
 CN 1H-1,2,3-Triazole-1-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-07-8 HCPLUS
 CN Phosphoric acid, bis(1,1-dimethylethyl)[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 765287-15-8 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-[(4-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 765287-16-9 HCPLUS
 CN 2-Oxazolidinone, 3-(4-ethynyl-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.RN 765287-17-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(trimethylsilyl)ethynyl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 30 Sep 2004
GI

AB Title compds. represented by the formula I [wherein N-HET = (un)substituted 1-pyrazolyl, 1-imidazolyl, 1,2,3-triazol-1-yl, etc.; Q = (un)substituted heteroaryl Ph, pyridinyl, thieryl, etc.; and pharmaceutically acceptable salts or an in-vivo hydrolyzable ester thereof] were prepared as MAO-A (mono-amine oxidase) inhibitors. For example, coupling reaction of (SR)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one with 5-(tributylstannyl)-3-methylisoxazole gave II. II showed decreased MAO-A potency with K_i value of 21 μ M/ml. Thus, I and their pharmaceutical compds. are useful as antibacterial agents.

ACCESSION NUMBER: 2004799583 HCAPLUS

DOCUMENT NUMBER: 141:314336

TITLE: Preparation of 1,3-oxazolidin-2-one derivatives as antibacterial agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 70 pp.

COPEN: PIX002

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083205	A1	20040930	WO 2004-GB1119	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SK, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BZ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-6358 A 20030320

OTHER SOURCE(S): MARPAT 141:314336

IT 765912-32-1P 765912-34-3P 765912-36-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES: (Uses)

(preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)


RN 765912-32-1 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 765912-34-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 765912-36-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1-phenylmethyl)-1H-1,2,3-triazol-4-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 501939-98-5P 501940-28-9P 765912-54-7P
765912-55-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)


RN 501939-98-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 501940-28-9 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 765912-54-7 HCAPLUS
CN 2-Oxazolidinone, 3-(4-ethynyl-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-55-8 HCAPLUS
 CN 2-Oxaazolidinone, 3-[3-fluoro-4-[(trimethylsilyl)ethyl]phenyl]-5-((4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 triazol-4-yl)methyl)- β -D-glucopyranosyl]oxy)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 756825-24-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[3-1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-[(propyl)- β -D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Bifunctional heterocyclic glycosides I were prepared, wherein X is a linear linker; Y is heterocycle; J is H, macrocycle, acyl, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic carbocycle, L is CO, CO₂, amide; n is 0-1; R₁-R₃ are independently H, Ln-alkyl, Ln-alkenyl, Ln-alkynyl; Ln-aromatic; R₂R₃ together with the N atom to which they are bonded, form 5-7 membered saturated, unsatd., or aromatic heterocycle, useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. Thus, macrolide glycoside II was prepared as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agent (no biol. data).

ACCESSION NUMBER: 2004-756728 HCAPLUS

DOCUMENT NUMBER: 141:260999

TITLE: Preparation of bifunctional heterocyclic azithromycin compounds useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents

INVENTOR(S): Farmer, Jay J.; Sutcliffe, Joyce A.; Bhattacharjee, Ashoke

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078770	A1	20040916	WO 2004-US6892	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KW, LK, LR, LS, LT, LU, LV, MA, MD, MG, MR, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CY, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG	AA	20040916	CA 2004-2517970	20040305
CA 2517970	CA	2004-0916	US 2003-451951P	P 20030305
PRIORITY APPLN. INFO.:			WO 2004-US6892	W 20040305

OTHER SOURCE(S): MARPAT 141:260999


IT 756825-22-6P 756825-24-8P 756825-25-9P

RL: BSU (Biological study, unclassified); IMP (Industrial manufacture); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of bifunctional heterocyclic azithromycin compds. useful as antiinfective antiproliferative antimicrobial and prokinetic agents)


RN 756825-22-6 HCAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

PAGE 1-A





PAGE 1-B





RN 756825-25-9 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[[2-1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-[(propyl)- β -D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756825-26-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadec-15-one, 11-[[3,6-dideoxy-3-(dimethylamino)-4-O-[[1-[(5-(3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-trhydro-4-yl carbonyl]-β-D-glucopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The title compds. I [R1 = -NH(C=O)R5 or (substituted)1,2,3-Triazolyl; W = O or S; R2, R3 = H, F, Cl, OMe, and Et; R5 = H, alkyl, Me, 5-halo-2-thienyl etc.; R6 = hydroxymethyl] were prepared as antibacterial agents. For example, compound II was prepared from (SR)-3-(3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one in a multi-step synthesis. Antibacterial properties of II against several types of bacteria were determined [MIC(µg/mL): methicillin sensitive and quinolone sensitive staphylococcus aureus (0.25), methicillin resistant and quinolone resistant staphylococcus aureus (0.5), streptococcus pneumoniae (0.02), haemophilus influenza (4), and Moraxella catarrhalis (0.5)].

ACCESSION NUMBER: 2004756715 HCPLUS

DOCUMENT NUMBER: 141260739

TITLE: Preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Carcangue, Daniel Robert

PATENT ASSIGNEE(S): Astrazeneca AB, Sweden; Astrazeneca UK Limited

SOURCE: PCT Int. Appl. 107 pp.

CODEN: PXXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078753	A1	20040916	WO 2004-GB730	20040224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, H2, NA, NI, BV, GH, GR, KE, LS, MW, H2, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, MR, NE, SN, TD, TG				




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

OTHER SOURCE(S): MARPAT 141:260739

IT 702681-58-1P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)

RN 702681-58-1 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 756873-54-8P 756873-57-1P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)

RN 756873-54-8 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5R)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 756874-57-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-95-3P 700370-33-8P 700370-36-1P
 700370-37-2P 700370-39-4P 700370-40-7P

RN: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)

RN 501939-95-3 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-33-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(bromomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756874-06-3 HCAPLUS
 CN Phosphoric acid, bis[1,1-dimethylethyl] [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 700370-36-1 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-37-2 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-39-4 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-(hydroxymethyl)-1H-1,2,3-

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 756874-09-6 HCAPLUS
 CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A
 IT 756873-76-4P 756873-84-4P 756873-87-7P
 RN: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (pro-drug; preparation of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)
 RN 756873-76-4 HCAPLUS
 CN Glycine, N,N-dimethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-



PAGE 1-B

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
isoxazolyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HC1


RN 756873-84-4 HCAPLUS
CN Pentanoic acid, 5-[(1,1-dimethyllethoxy)carbonyl]methylamino-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



PAGE 1-B

~NET₂


RN 702681-66-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 756873-87-7 HCAPLUS

CN Pentanoic acid, 5-(methylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

~NHMe


IT 702681-56-9P 702681-66-1P 702682-78-9P
756873-58-2P 756873-59-3P 756873-60-6P
756873-61-7P 756873-62-8P 756873-63-9P
756873-64-0P 756873-65-1P 756873-66-2P
756873-67-3P 756873-68-4P 756873-69-5P
756873-70-6P 756873-71-9P 756873-72-0P
756873-73-1P 756873-74-2P 756873-75-3P
756873-77-5P 756873-78-6P 756873-79-7P
756873-80-0P 756873-81-1P 756873-82-2P
756873-83-3P 756873-85-5P 756873-86-6P
756873-88-9P 756873-89-9P 756873-91-3P
756873-92-4P 756873-93-5P 756873-94-6P
756873-95-7P 756873-96-8P 756873-97-9P
756873-98-0P 756873-99-1P 756874-00-7P
756874-01-8P 756874-02-9P 756874-03-0P

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 756874-04-1P 756874-05-2P
RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pro-drug; prepn. of hydroxymethyl dihydroisoxazole derivs. useful as antibiotic agents)
RN 702681-56-9 HCAPLUS
CN β -Alanine, N,N-dimethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

~OMe

RN 756873-58-2 HCAPLUS
CN Hexanedioic acid, ethyl [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OEt

RN 756873-59-3 HCAPIUS
 CN β -Alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-60-6 HCAPIUS
 CN Butanoic acid, 4-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-B




RN 756873-62-8 HCAPIUS
 CN Acetic acid, methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-63-9 HCAPIUS
 CN Propanoic acid, 3-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-64-0 HCAPIUS
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-




PAGE 1-B


-NMe₂

RN 756873-61-7 HCAPIUS
 CN Pentanoic acid, 5-[(methoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 756873-65-1 HCAPIUS
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OMe

RN 756873-66-2 HCAPIUS
 CN Pentanedioic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OMe

RN 756873-67-3 HCAPLUS
 CN Butanoic acid, 4-methoxy-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OMe


RN 756873-68-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(acetyl oxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-69-5 HCAPLUS
 CN 1,2-Cyclohexanedicarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-70-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(phosphonoxy)methyl]-3-

Absolute stereochemistry.

● 2 NH₃


RN 756873-71-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(sulfoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-72-0 HCAPLUS
 CN 4-Piperidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-73-1 HCAPLUS
 CN Pentanoic acid, 5-(dimethylamino)-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-NMe₂



RN 756873-74-2 HCAPLUS
 CN Butanedioic acid, mono[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolylmethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

 $\sim \text{CO}_2\text{H}$


RN 756873-75-3 HCAPLUS
 CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

 $\bullet \text{Cl}^-$

RN 756873-79-7 HCAPLUS
 CN Carbonic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl 3-methoxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


 $\sim (\text{CH}_2)_3\text{OCH}_3$

RN 756873-80-0 HCAPLUS
 CN Pyrazinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

 ≈ 0

RN 756873-77-5 HCAPLUS
 CN Pentanoic acid, 5-[(ethoxycarbonyl)amino]-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-79-6 HCAPLUS
 CN Ethanaminium, 2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy-, chloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 756873-81-1 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-82-2 HCAPLUS
 CN Ethanaminium, 2-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methoxy carbonyl oxy-, N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



 $\sim (\text{CH}_2)_3\text{OCH}_3$

RN 756873-80-0 HCAPLUS
 CN Pyrazinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

● Cl⁻—N⁺Me₃

RN 756873-83-3 HCAPLUS
 CN Pentanoic acid, 5-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 756873-88-8 HCAPLUS
 CN Pentanoic acid, 5-[(dimethylamino)acetyl]methylamino]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-95-5 HCAPLUS
 CN Butanoic acid, 4-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-86-6 HCAPLUS
 CN Hexanoic acid, 6-[(methoxycarbonyl)methylamino]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-89-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(6-[(5S)-5-[(β-D-glucopyranosyloxy)methyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-91-3 HCAPLUS
 CN Glycine, N-methyl-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-92-4 HCAPIUS
 CN L-alanine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756873-93-5 HCAPIUS
 CN L-Valine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 756873-94-6 HCAPIUS
 CN L-Leucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 756873-95-7 HCAPIUS
 CN Glycine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756873-96-8 HCAPIUS
 CN L-isoleucine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756873-97-9 HCAPIUS
 CN L-Glutamine, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 756873-98-0 HCAPIUS
 CN L-Aspartic acid, 1-[(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 756873-99-1 HCAPLUS
 CN L-Aspartic acid, 4-[(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

-CO₂H

RN 756874-00-7 HCAPLUS
 CN L-lysine, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.

RN 756874-03-0 HCAPLUS
 CN Acetic acid, [2-[(methoxycarbonyl)methylamino]ethoxy]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B

RN 756874-04-1 HCAPLUS
 CN Acetic acid, [2-(methylamino)ethoxy]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-


PAGE 1-A



PAGE 1-B

RN 756874-01-0 HCAPLUS
 CN L-Phenylalanine, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 756874-02-9 HCAPLUS
 CN L-Proline, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

PAGE 1-B


PAGE 1-C

RN 756874-05-2 HCAPLUS
 CN L-Isoleucine, N-methyl-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 756874-04-1 HCAPLUS
 CN Acetic acid, [2-(methylamino)ethoxy]-, [(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-



● HC1

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-R8 = H, halo, NH2, glycylamino, (un)substituted alkony; T = halo, OH, (un)substituted C1-8 alkony, (un)substituted C1-8 alkanoxy, NH2, N3, (un)substituted unsatd. heterocycl, etc.], useful for controlling (drug-resistant) bacteria, are prepared by conversion of 3-(substituted phenyl)-2-oxooxazolidines II (R1-R4, O = same as above; X = iodine, Br, Cl, halosulfonyloxy, diaryl phosphate residue) into 3-(boron-substituted phenyl)-2-oxooxazolidines II (R1-R4, O = same as above; X = BrOR10, R9, R10 = OH, C3-8 linear alkyl(oxy), C3-8 branched alkyl(oxy) may be linked); then coupling with oxazolidinylbenzenes III (R5-R8, T = same as above; Y = iodine, Br, Cl, halosulfonyloxy, diaryl phosphate residue). Thus, coupling of 3-(3-fluoro-4-iodophenyl)-2-oxo-5-(R)-phthalimidomethyloxazolidine with 5(S)-acetamidomethyl-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxaborolan-2-yl)phenyl]-2-oxooxazolidine in the presence of K phosphate and tetrakis(triphenylphosphine)palladium in DMSO gave the corresponding biphenyl compound with 66% yield, which showed MIC of 2 μ g/mL against methicillin-resistant *Staphylococcus aureus*.

ACCESSION NUMBER: 2004-588234 HCAPLUS

DOCUMENT NUMBER: 141140417

TITLE: Preparation of novel biphenyls, their intermediates, and their use as bactericides

INVENTOR(S): Shikawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Fujita, Toshiaki; Maehashi, Kazunori; Yoshida, Satoshi

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

Jpn. Kokai Tokkyo Koho, 185 pp.

SOURCE: CODEN: JKOKAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004203809	A2	20040722	JP 2002-376218	20021226
PRIORITY APPLN. INFO.:			JP 2002-376218	20021226

OTHER SOURCE(S): MARPAT 141:140417

IT 724793-19-5P

RL: PAC (Pharmacological activity); PCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (oxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)

RN 724793-19-5 HCAPLUS

CN Carbamic acid, [(1-[(5R)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro-1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

—NHAc

IT 724793-94-3P 724793-13-9P 724793-15-1P


724793-20-8P 724793-78-6P 724793-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (oxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)

RN 724793-94-3 HCAPLUS

CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-13-9 HCAPLUS

CN Carbamic acid, [2-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

—OBu-t


RN 724793-15-1 HCAPLUS

CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CN 1

CRN 724793-14-0
CHF C24 H23 F2 N7 O5

Absolute stereochemistry.




CN 2

CRN 76-05-1




RN 724793-20-8 HCAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(5-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-78-6 HCAPLUS
CN Carboxic acid, [(1-[(5R)-3-[4'-(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-5-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-79-7 HCAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-95-3P 724793-90-2P 724793-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of (oxazolidinyl)biphenyls as bactericides for (dye-resistant) bacteria)
RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-90-2 HCAPLUS
CN Carboxic acid, [(1-[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-91-3 HCAPLUS
CN Carboxic acid, [(1-[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 pyrimidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 716379-05-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-5-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 716379-09-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 716379-12-3 HCAPLUS

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 10 Jun 2004
 GI



AB Title compds. (R1a)-m-A-C-B-CH2-R1b [C = biaryl group; A, B = dihydroisoxazoles; oxazolidinones; R1a = CN, carbonyl, alkoxycarbonyl, aryl, etc.; m = 0-2; R1b = OH, silyl oxy, etc.; I] are prepared. For instance, (5R)-3-(3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ene (preparation given) is coupled to 5,5-bis([(tert-butylidimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702679-98-9, (5R)-3-[4'-(5,5-Bis([(tert-butylidimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-59-57 702680-93-2#, (5R)-3-[4-[6-((1R)-1,2-Dihydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridazin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one.

ACCESSION NUMBER: 20041467903 HCAPLUS

DOCUMENT NUMBER: 141:38599

TITLE: Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents

INVENTOR(S): Carcangue, Daniel Robert; Gravestock, Michael Barry; Hale, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter

PATENT ASSIGNEE(S): AstraZeneca AB, Sweed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048392	A1	20040610	WO 2003-GB5087	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, HK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KS, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LU, RC, NL, PT, RO, SE, SI, SK, TR, DF, DU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L12 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2-Oxazolidinone, 3-[4-[2-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-5-pyrimidinyl]-3-fluorophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RN 716379-05-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-5-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

RN 716379-09-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)

RN 716379-12-3 HCAPLUS

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ED Entered STN: 10 Jun 2004
 GI


IT 501940-91-6P 702679-77-4P, (5R)-3-[4'-(5,5-Bis([(tert-butylidimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702679-98-9P, (5R)-3-[4'-(5,5-Bis([(tert-butylidimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-59-57 702680-93-2P, (5R)-3-[4-[6-((1R)-1,2-Dihydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridazin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one.

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PRP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of oxazolidinone/isoxazoline derive as antibacterial agents)

PR: 501940-91-6 HCAPLUS


CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702679-77-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[2-(4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702679-98-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[5-[5,5-bis[[{(1,1-dimethylethyl)dimethylsilyl]oxy]met-hyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-89-5 HCAPLUS
 CN 5-Isoxazolcarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-93-1 HCAPLUS
 CN 5-Isoxazolcarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-83-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-((5S)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 702679-95-6P, (5R)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-3,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-03-3P
 (5R)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-3,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-11-3P 702680-16-8P, (5R)-3-[4'-(4,5-Dihydroisoxazol-3-yl)-2-fluoro-3,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-21-5P
 (5R)-3-[4'-(4,5-Dihydroisoxazol-3-yl)-2-fluoro-3,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-22-7P, (5R)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702680-33-1P
 702680-33-1P, (5R)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-fluoromethyl)-1H-1,2,3-triazol-1-ylmethyl]-1,3-oxazolidin-2-one 702680-46-4P 702680-51-1P 702680-61-3P
 702680-61-3P 702680-69-1P 702680-73-7P, (5R)-3-[3-Fluoro-4-[(6-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)pyridin-3-yl)phenyl]-5-[(4-fluoromethyl)-1H-1,2,3-triazol-1-ylmethyl]-1,3-oxazolidin-2-one 702680-85-1P 702680-93-3P
 702680-93-3P 702681-01-4P 702681-07-0P
 702681-11-6P 702681-15-0P 702681-20-7P
 702681-22-9P 702681-26-3P 702681-31-0P
 702681-39-8P 702681-40-1P 702681-42-3P
 702681-44-5P 702681-47-8P 702681-54-7P
 702681-56-9P 702681-61-6P 702681-64-9P
 702681-66-1P 702681-68-4P 702681-71-0P
 702681-72-3P 702681-87-6P, (5R)-3-[4-[(5R)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702681-97-8P
 (5R)-3-[4-[(5S)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-01-7P, (5R)-3-[4-[(5S)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-13-1P, (5R)-3-[4-[(5S)-5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-26-6P 702682-29-0P
 702682-32-4P 702682-43-7P, (5R)-3-[3-Fluoro-4-[(6-(5S)-5-[(2-hydroxyethyl)thio]methyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-54-2P 702682-72-2P 702682-78-8P
 702682-88-0P

L12 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of oxazolidinone/isoxazoline derivs. as antibacterial agents)


RN 702680-95-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-03-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-11-3 HCAPLUS
 CN 5-Isoxazolacetonitrile, 3-[2'-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 702680-16-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-21-5 HCAPIUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 702680-23-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-35-1 HCAPIUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 702680-46-4 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-1-oxido-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-51-1 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-(6-[4,5-dihydro-5-(tetrahydro-3-hydroxy-1,1-dioxido-3-thienyl)-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 702680-61-3 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxy-1-methylethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-65-7 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-4,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-69-1 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[5-(2,2-diethoxyethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-73-7 HCPLUS
 CN 2-Oxazolidinone, 3-[4-(6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 702680-85-3 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[5-(4,5-dihydro-5-(2-hydroxyethyl)-3-isoxazolyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-95-3 HCPLUS
 CN 5-Isoxazolylcarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]phenyl]-2-pyridinyl]-4,5-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-99-7 HCPLUS
 CN 5-Isoxazolylcarboxamide, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl]phenyl]-2-pyridinyl]-4,5-dihydro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-01-4 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(2-hydroxyethyl)sulfonyl]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-07-0 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxyphenylmethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-11-6 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(1-hydroxycyclopentyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 702681-15-0 HCPLUS
 CN 1-Naphthaleneacetic acid, 1-[3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 702681-20-7 HCPLUS
 CN 2-Oxazolidinone, 3-[(6-[4,5-dihydro-5-(1-hydroxy-2-methylpropyl)-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-22-9 HCPLUS
 CN 2-Oxazolidinone, 3-[(6-[4,5-dihydro-5-[(2-(4-pyridinyl)ethyl)amino]methyl]-3-isoxazolyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 702681-26-3 HCPLUS
 CN 2-Oxazolidinone, 3-[(6-[4,5-dihydro-5-(4-hydroxy-1-methyl-4-piperidinyl)-3-isoxazolyl]-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702681-31-0 HCPLUS
 CN 2-Oxazolidinone, 3-[(6-[4,5-dihydro-5-[[2-(4-pyridinyl)ethyl]sulfonyl]methyl]-3-isoxazolyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Page 9529/11/2005

PAGE 1-A




PAGE 1-B



RN 702681-39-8 HCPLUS
 CN Glycine, N,N-dimethyl-, [3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 702681-40-1 HCPLUS
 CN Pentadecanoic acid, [3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

L12 ANSWER 22 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-(5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl)-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-42-3 HCPLUS
 CN 2,5,8,11,14-Pentaoxapentadecanoic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 22 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Piperidinocarboxylic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-47-8 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(phosphonoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)]-, diaminium salt, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



RN 702681-44-5 HCPLUS



●2 NH3


RN 702681-54-7 HCPLUS
 CN Propanoic acid, 2,2-dimethyl-, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 702681-56-9 HCPLUS
 CN β -Alanine, N,N-diethyl-, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

-NET2


RN 702681-61-6 HCPLUS
 CN Butanedioic acid, [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 702681-60-5
 CMF C26 H25 F N6 O7

L12 ANSWER 22 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



PAGE 1-B

-CHMe

CH 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 702681-64-9 HCPLUS
 CN Butanedioic acid, ethyl [3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 702681-63-8
 CMF C27 H27 F N6 O7

Absolute stereochemistry.



PAGE 1-B


-OEt

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 702681-66-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, [(5S)-3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-69-4 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [(3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methoxy]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 702681-68-3
CHF C27 H29 F N6 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


-Bu-t

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 702681-71-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-[(4-nitrobenzoyl)oxy]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-NO2

RN 702681-73-0 HCAPLUS
CN Butanedioic acid, mono[(3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl)methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-CO2H


RN 702681-87-6 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-97-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(5S)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-01-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5R)-5-[(1S)-1,2-dihydroxyethyl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-13-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-21-1 HCAPLUS
 CN Propanoic acid, 3-methoxy-, (2R)-2-[(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxymethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

PAGE 1-A




PAGE 1-B




RN 702682-29-9 HCAPLUS
 CN Carbonic acid, (2R)-2-[(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-2-hydroxymethyl 2-methoxymethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



● 4 NH₃

RN 702682-43-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2-hydroxymethyl)thio]methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702682-56-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(trifluoromethoxy)methyl]-3-


L12 ANSWER 22 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 1-isoxazolyl)-1-(3-pyridinyl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702682-72-2 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2,2,2-trifluoroethoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-78-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-[(2-methoxyethoxy)methyl]-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-OMe

RN 702682-89-0 HCAPIUS
 CN 2-Oxazolidinone, 3-[4-[6-[(5S)-4,5-dihydro-5-(methoxymethyl)-3-isoxazolyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-98-6, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-27-8, (5R)-3-(3-Fluoro-4-(trimethylstannyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-36-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)
 RN 501939-98-6 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 22 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501940-27-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-36-1 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-98-9P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 501940-28-9P, (5R)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-33-8P, 700370-37-2P

L12 ANSWER 22 OF 41 HCAPIUS COPYRIGHT 2005 ACS on STN (Continued)

702680-25-9P, (5R)-3-[4-[(5,5-Bis[(tert-butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-37-3P, (5R)-3-[4-[(5,5-Bis[(tert-butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 702681-58-1P, 702681-88-4P, 702681-99-0P
 702682-16-4P, (5R)-3-[4-[(5,5-Bis[(tert-butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702682-35-7P, 702682-37-9P, 702682-47-1P, (5R)-3-[4-[(5,5-Bis[(tert-butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl]pyridin-3-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)


RN 501939-95-3 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-28-9 HCAPIUS
 CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-33-8 HCAPIUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCPLUS
CN 2-Oxazolidinone, 3-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-25-9 HCPLUS
CN 2-Oxazolidinone, 3-[(4'-(5,5-bis([(1,1-dimethylethyl)dimethylsilyl]oxy)methyl)-4,5-dihydro-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-37-3 HCPLUS
CN 2-Oxazolidinone, 3-[(4'-(5,5-bis([(1,1-dimethylethyl)dimethylsilyl]oxy)methyl)-4,5-dihydro-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-97-5 HCPLUS
CN 5-Isoxazolecarboxylic acid, 3-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-4,5-dihydro-pentafluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-49-0 HCPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [3-[5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-59-1 HCPLUS
CN 2-Oxazolidinone, 3-[(4-[(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-85-4 HCPLUS
CN 2-Oxazolidinone, 3-[(4-[(5S)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-99-0 HCPLUS
CN 2-Oxazolidinone, 3-[(4-[(5S)-5-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-16-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[6-[5,5-bis([(1,1-dimethylethyl)dimethylsilyl]oxy)methyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-35-7 HCAPLUS
 CN Phosphoric acid, (1R)-1-[(5S)-3-[5-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolidinyl]phenyl)-2-pyridinyl]-4,5-dihydro-5-isoxazolyl]-1,2-ethanediyl tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-37-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[6-[(5S)-5-((1R)-1,2-bis(phosphonoxy)ethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702682-47-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[6-[(5S)-5-(chloromethyl)-4,5-dihydro-3-isoxazolyl]-3-pyridinyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Isoxazolinyl oxazolidinone compds. of formula I ($RICH_2-A-C-B-CH_2R_2$ [A, B = oxazolidinone, isoxazoline; C = (substituted) diaryl group; $R_1, R_2 = OH$, trialkylsilylony, acyloxy, heteroaryl, etc.]) are prepared as antibacterial agents. Methods for making compds. of formula I, compns. containing them and their use as antibacterial agents are also described. Thus, II was prepared, and had MIC of 0.5 μ g/ml against *Staphylococcus aureus*.


ACCESSION NUMBER: 2004167887 HCAPLUS
 DOCUMENT NUMBER: 141:23522
 TITLE: Preparation of isoxazolinyl oxazolidinone antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 78 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048370	A1	20040610	WO 2003-GB5082	20031124
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TA, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW, RW: BW, GH, GM, KE, LS, SD, SL, SZ, TZ, UG, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, LU, MC, NL, PT, RO, SE, SI, SK, TR, TW, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, ML, MR, NE, SN, TD, TG				
EP 1567521	A1	20050831	EP 2003-811806	20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, KK, HU, SK				
PRIORITY APPLN. INFO.: GB 2002-27701				A 20021128
OTHER SOURCE(S): MARPAT 141:23522			WO 2003-GB5082	20031124
IT 698981-84-IP 698981-84-IP				
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THER (Therapeutic use); BIOL (Biological study); PRP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of isoxazolinyl oxazolidinone antibacterial agents)				
RN 698981-84-9 HCAPLUS				
CN 2-Oxazolidinone, 3-[(4-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)				




RN 698981-94-1 HCAPIUS
CN 2-Oxazolidinone, 3-[4'-(5-[[{1,1-dimethylethyl}dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl]-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 698981-89-4P 698981-99-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazolinyl oxazolidinone antibacterial agents)
RN 698981-99-4 HCAPIUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 698981-99-6 HCAPIUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 501939-95-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazolinyl oxazolidinone antibacterial agents)
RN 501939-95-3 HCAPIUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. I [C = substituted biaryl; R1 = HET1, HET2; HET1 = N-linked 5-membered (un)saturated heterocyclic ring, etc.; R2 = N-linked 6-membered dihydroheterocyclic ring, etc., are prepared. For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to bis(pinacolato)diboron (DMSO, PdcCl2(dppf)-CH2Cl2, K2CO3) and the resulting adduct coupled to 5-(mono-2-(2-ethyl)-2H-tetrazol-5-yl)pyridine (DMF, H2O, K2CO3, (PPh3)4Pd) to give II. Compds. of the invention inhibit antibacterial activity with MIC = 0.01 - 256 µg/mL; II has MIC < 0.06 for Streptococcus pneumoniae.

ACCESSION NUMBER: 2004-467876 HCAPIUS

DOCUMENT NUMBER: 141:23521

TITLE: Preparation of substituted oxazolidinones as antibiotics

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200404350	A2	20040610	WO 2003-GB5091	20031124
WO 200404350	A3	20041021		


W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,




IT 700370-42-9, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted oxazolidinones as antibiotics)

RN 700370-42-9 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-95-3P, (5R)-3-[3-Fluoro-4-(iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-33-8P 700370-34-9P
700370-36-1P, (5R)-3-[3-Fluoro-4-(iodophenyl)-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 700370-37-2P,
(5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-fluoromethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
700370-38-3P 700370-39-4P, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-hydroxymethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
700370-40-7P, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
700370-43-0P, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-bromomethyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
700370-49-1P, (5R)-3-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
700370-53-2P, (5R)-5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one




RN 700370-36-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-37-2 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-38-3 HCAPLUS
CN Boronic acid, [2-fluoro-4-[(5R)-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
700370-54-3P, 1-[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl]-1H-1,2,3-triazole-4-carboxaldehyde
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted oxazolidinones as antibiotics)


RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-33-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-34-9 HCAPLUS
CN Boronic acid, [2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 700370-39-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-iodophenyl]-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-40-7 HCAPLUS
CN 2-Oxazolidinone, 5-[(4-(bromomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-iodophenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-43-0 HCAPLUS


L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 700370-52-1 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 700370-53-2 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-(3-fluoro-4-iodophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 700370-54-3 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbomaldehyde, 1-{[(5R)-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 23 Apr 2004
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazolyl, dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)n, n = 0-1; X = N, CH; Y = N, O, S; Z = NHCO1, NHCS1, CONH1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of CBZ-protected benzamidine II, e.g., prepared from benzyl 3-pyrrolidine-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylaminoo-1-chloromethyl ethyl ester afforded oxazolidinone III in 62% yield. In *S. aureus* Min. Inhibitory Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 μ g/ml, i.e., the MIC value of oxazolidinone III was 1 μ g/ml. Compds. I are claimed useful for the treatment of skin and eye infections.

ACCESSION NUMBER: 2004:333714 HCAPLUS

DOCUMENT NUMBER: 1401357327

TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents

INVENTOR(S): Gordov, Mikhail Fedor; Renslo, Adam; Patel, Dinesh Vinooobhai

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KG, KW, KZ, LC, LI, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PL, PT, RO, RU, SG, SD, SE, SG, SK, SI, SV, SY, TJ, TM, TW, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
NW: GH, GR, KE, MW, MZ, SD, SI, SZ, TZ, UG, ZW				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, ES, FI, FR, GB, GA, HU, IE, IT, LU, MC, NL, PT, RO, SB, SI, SK, TR, BF, BU, CF, CO, CI, CR, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004127530	A1	200404071	US 2003-677451	20031002
US 6975784	B2	20050405		
CA 2501352	AA	20040422	CA 2003-2501352	20031003
EP 1549641	A1	20050706	EP 2003-770310	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015106	A	20050809	BR 2003-15106	20031003
PRIORITY APPLN. INFO.:			US 2002-417735P	P 20021009
			WO 2003-US28560	W 20031003

OTHER SOURCE(S): MARPAT 140:357327

IT 681424-72-79
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L12 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 antibiotics and related compds. as

RN 681424-73-7 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1a,5a,6a)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 681424-72-6
 CHF C18 H17 F2 N5 O4

Absolute stereochemistry.



CH 2

CRN 76-05-1
 CHF C2 H F3 O2





IT 681425-60-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or agent)
 (Preparation) of bicyclic[3.1.0]oxazolidinones and related compds. as antibiotics and related compds. as

RN 681425-60-5 HCAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Oxopyridinylphenyl oxazolidinones, e.g. of formula I [W = O, S; R1 = NH2, NH-alkyl, alkyl, alkoxy, etc.; R2, R3 = H, Cl, F, Me, NH2, OH; R4 = H, halo, NH2, OH, CN, alkyl, alkoxy, etc.], are prepared as antibacterial agents, which have activity against both Gram-pos. and Gram-neg. bacteria. The II was prepared, and had MIC of 1 μ g/mL against HINF 30063.

ACCESSION NUMBER: 2004-33712 HCAPLUS

DOCUMENT NUMBER: 1401339319

TITLE: Preparation of oxopyridinylphenyl oxazolidinones as Gram-positive and Gram-negative antibacterial agents

INVENTOR(S): Gordeev, Mikhail Fedor; Singh, Upinder; Patel, Dinesh Vinodbhai May, Paul Dennis

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200403449	A1	20040422	WO 2003-1B4380	20031003
W: AE, AG, AL, AM, AT, AU, NZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, ET, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KW, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CL, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2499105	AA	20040422	CA 2003-2499105	20031003
EP 1554273	A1	20050720	EP 2003-807940	20031003


L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003015206 A 20050816 BR 2003-15206 20031003
US 2005070580 A1 20050331 US 2004-497626 20040603
PRIORITY APPLN. INFO.: US 2002-417492P P 20021010
WO 2003-1B4380 W 20031003

OTHER SOURCE(S): MARPAT 140:339319

IT 680614-95-3P 680614-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxopyridinylphenyl oxazolidinones as antibacterial agents)
RN 680614-95-3 HCAPLUS
CN 4(1H)-Pyridinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 680614-96-4 HCAPLUS
CN 4(1H)-Pyridinone, 2,3-dihydro-1-[4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Apr 2004

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I (A = C(=O); B = O, NR2, S(=O)R, C(=O), C(=S), C(=NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(=O)R4, CHO, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, Cl-8-alkoxy, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); NR2R2 = 5 to 8-membered (un)saturated carbocycle or heterocycle (containing one or more N, S, O); R3 = H, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, Cl-8-acyl, (un)saturated or aromatic C3-8-carbocycle, (un)saturated or aromatic 5 to 7-membered heterocycle (containing one or more N, S, O); NR3R3 = 5 to 8-membered (un)saturated 7-membered carbocycle or heterocycle (containing one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NR3COR3, C(=O)NR3R3, Cl-8-alkyl, C2-8-alkenyl, C2-8-alkynyl etc.; D = D1, D2, D3, D4; E = di- or para-substituted Ph, substituted 4-vinylphenyl; G = Cl-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkoxy, Cl-8-alkylthio, Cl-8-acyl, (un)saturated or aromatic C5-10-carbocycle, (un)saturated or aromatic 5 to 10-membered heterocycle (containing one or more N, S, O); Z = C(=O)N, O, S; dashed line = single or double bond) or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional heterocyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin derivative II was prepared from N-(desmethylerythromycin), via N-alkylation with EC-1bifunctional C(=O)CH2CH2OTs, and cycloaddn. with azide III.

ACCESSION NUMBER: 2004292029 HCAPLUS

DOCUMENT NUMBER: 14032158

TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents

INVENTOR(S): Wan, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; McConnell, Timothy S.; Ippolito, Joseph A.; Abelson, John H.

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030925
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
morpholinyl-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)- (5CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 677726-17-9P 677726-31-7P 677726-85-1P
677726-86-3P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation and hydrolysis of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-17-9 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl)oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (5CI) (CA INDEX NAME)

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, MN, MZ, NI, NO, NZ, LR, LS, LT, LV, MA, MD, MG, MK, MM, MU, MX, MZ, SE, SG, SK, SL, SY, TJ, TM, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SI, S2, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LU, NL, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GP, GW, HL, MR, NE, SN, TD, TG
US 2005197334 A1 20050908 US 2003-671326 20030925
CA 2500158 AA 20040408 US 2003-2500158 20030926
EP 1543017 A2 20050622 EP-2003-770506 20030926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, PRIORITY APPLN. INFO.: US 2002-414207P P 20020926
US 2003-448216P P 20030219
WO 2003-US30478 W 20030925

OTHER SOURCE(S): MARPAT 140:321150


IT 677726-23-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation and N-alkylation by, of des-N-methylerythromycin; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiinflammatory and prokinetic agents)

RN 677726-23-7 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[(4-[2-[(4-methylphenyl)sulfonyloxy]ethyl]-1H-1,2,3-triazol-1-yl)methyl]- (5CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 677726-15-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation and N-dealkylation of; preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)


RN 677726-15-7 HCAPLUS

CN Erythromycin, N-demethyl-N-[2-1-[(5R)-3-[3-fluoro-4-(4-


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
3,4,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl)oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (5CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 677726-31-7 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl)oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (5CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-85-1 HCPLUS
 CN 1-Oxa-6-azacycloheptadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl)methoxy]ethyl)methylamino]-8-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-86-2 HCPLUS
 CN 1-Oxa-6-azacycloheptadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluorophenyl)-2-oxo-4-(morpholinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-
 triazol-4-yl)methoxy]ethyl)methylamino]-8-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,6R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 677726-19-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and tosylation of; preparation of bifunctional heterocyclic
 compds. for use as antiinfective, antiproliferative, antiinflammatory and
 prokinetic agents)
 RN 677726-19-1 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[(4-(3-
 hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 677726-37-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation and tosylation of; preparation of bifunctional heterocyclic
 compds. for use as antiinfective, antiproliferative, antiinflammatory and
 prokinetic agents)

RN 677726-37-3 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[(4-(2-
 hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 677726-11-3P 677726-12-4P 677726-13-5P
 677726-14-6P 677726-16-8P 677726-18-0P
 677726-26-0P 677726-27-1P 677726-29-2P
 677726-29-3P 677726-30-6P 677726-33-9P
 677726-34-0P 677726-35-1P 677726-36-2P
 677726-45-4P 677726-47-5P 677726-48-3P
 677726-49-7P 677726-50-0P 677726-51-1P
 677726-52-2P 677726-53-3P 677726-54-4P
 677726-55-5P 677726-57-7P 677726-58-8P

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

677726-60-28 677726-62-49 677726-63-59
 677726-65-78 677726-66-89 677726-68-09
 677726-70-49 677726-72-69 677726-73-79
 677726-74-89 677726-75-99 677726-76-09
 677726-77-18 677726-78-29 677726-79-39
 677726-80-69 677726-81-79 677726-82-89
 677726-83-99 677726-84-09 677726-87-39
 677726-88-49 677726-89-59 677726-90-69
 677727-77-49 677727-78-59 677727-79-69
 677727-80-99 677727-81-09 677727-82-19
 677727-83-29 677727-84-39 677727-85-49
 677727-86-59 677727-87-69 677727-88-79
 677727-89-89 677727-90-19 677727-91-29
 677727-92-39 677727-93-49 677727-94-59
 677727-95-69 677727-96-79 677727-97-89
 677727-98-99 677727-99-09 677728-00-69
 677728-01-79 677728-02-89 677728-03-99
 677728-04-09 677728-42-99 678162-71-3DP,
 trans-cyclohexanol isomers


RL: SPN (Synthetic preparation); THW (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN: 677726-11-3 HCAPLUS

CN: 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[(2-hydroxyethyl)methylamino)methyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN: 677726-12-4 HCAPLUS

CN: 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[(2-hydroxyethyl)methylamino]ethyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN: 677726-13-5 HCAPLUS

CN: 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[[4-[(2-hydroxyethyl)methylamino]propyl]-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN: 677726-14-6 HCAPLUS

CN: D-xylo-Hexose, 3,4,6-trideoxy-3-[[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN: 677726-16-0 HCAPLUS

CN: Erythromycin, N-methyl-1-N-[3-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L12 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A




RN: 677726-18-0 HCAPLUS


CN: 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-trideoxy-3-[[3-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,6R,8R,10R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-26-0 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-tri-4-yl)ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-27-1 HCAPLUS
 CN Erythromycin, N-[2-[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 677726-28-2 HCAPLUS
 CN Erythromycin, N-[3-[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]propyl]-N-demethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

Ac


PAGE 2-A




RN 677726-29-3 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino)-3,4,6-trideoxy- β -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -D-ribopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





RN 677726-30-6 HCAPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A








RN 677726-33-9 HCAPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-34-0 HCAPLUS
 CN Erythromycin, N-[2-[1-[(5R)-3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-N-demethyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-35-1 HCAPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-36-2 HCAPLUS
 CN Erythromycin, 3-de[2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-N-demethyl-N-[2-[1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


PAGE 1-B



RN 677726-46-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(2-fluoro-4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




RN 677726-47-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[4-[(1R,2R)-2-(diethylamino)-1,3-dihydroxypropyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-48-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[4-(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-49-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[1-[(5R)-3-[4-[(2-acetyl)ethyl]methylamino]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]-3,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[4-(2-hydroxyethyl)methylamino]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-50-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(2-[1-[(5R)-3-[4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-51-1 HCAPLUS
 CN 1-oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-1-[(5R)-2-
 oxo-3-(3-pyridinyl)-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl]amino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 677726-52-2 HCAPLUS
 CN Erythromycin, N,N-dimethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-
 morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B


PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 677726-54-4 HCAPLUS
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
 hexopyranosyl)oxy]-N-demethyl-N-[2-[1-[(5R)-3-[3-fluorophenyl]-2-oxo-5-
 oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]-6-O-methyl-3-Oxo- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


RN 677726-53-3 HCAPLUS
 CN Erythromycin, 3-O-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
 hexopyranosyl)-N-demethyl-N-[2-[1-[(5R)-3-[3-fluoro-4-(4-
 morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 677726-55-5 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(4-dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 677726-58-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(1-[(5R)-3-(4'-cyano-2-fluoro-1,1'-biphenyl)-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A





RN 677726-57-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluoro-4-(1H-pyrrol-1-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-60-2 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]- β -D-xylo-hexopyranosyl)oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 27 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 677726-62-4 HCPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[4-(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl oxy-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-63-5 HCPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[1-[(5R)-3-(4-cyano-3-fluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-,

L12 ANSWER 27 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 677726-66-8 HCPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-1-[(5R)-3-[4-[(methylsulfonyl)amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl oxy-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 677726-65-7 HCPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]- β -D-xylo-hexopyranosyl oxy-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 27 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 677726-68-0 HCPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[1-[(5R)-3-[3-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl)methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,35,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-70-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[2-[1-[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl]oxy]-13-[2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[2-[1-[(5R)-3-[4-(aminosulfonyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-2-O-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-72-6 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[2-[1-[(5R)-3-[4-(dimethylamino)methylene]amino]sulfonyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 677726-73-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[2-[1-[(5R)-3-(3,4-dichlorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-74-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[2-[1-[(5R)-3-(3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-75-9 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[[3-[2-[1-[(5R)-3-(1,3-benzodioxol-5-yl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl- α -L-ribo-hexopyranosyl]oxy]-1H-1,2,3-triazol-4-yl]butyl]amino]- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677726-76-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[2-1-[(5R)-2-oxo-3-(5-quinoliny)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]ethyl]amino]- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A






PAGE 2-B

RN 677726-77-1 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl[4-1-[(5R)-2-oxo-3-(5-quinoliny)-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl]butyl]amino]- β -D-xylo-hexopyranosyl]oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A







RN 677726-78-2 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-
 [1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]butyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-79-3 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-
 [1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]butyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-80-6 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(4-
 [1-[(5R)-3-(4-acetylphenyl)-
 2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl)methylamino]-
 3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-
 methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,
 14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-81-7 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-
 [1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-82-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(4-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]butyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 677726-83-9 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-

L12 ANSWER 27 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 triazol-4-yl]-1-propenyl]-1-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry unknown.

RN 677726-84-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]-1-propenyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 677726-87-3 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-88-4 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)methyl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677726-89-5 HCPLUS
 CN 2H-Oxacycletetradecin[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-[(2-[1-[(5R)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677726-90-8 HCAPLUS
CN 2H-Omacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone,
4-ethylhydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-
3-[(2-[1-[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
triazol-4-yl)ethyl]amino)- β -D-xylo-hexopyranosyl]oxy]-
(3aS,4R,7R,9R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-77-4 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[2-[(5R)-3-
(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
yl]propyl]amino)- β -D-xylo-hexopyranosyl]oxy]-
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-78-5 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl[3-1-[(5R)-3-
(4-methyl-2-thiazolyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
yl]propyl]amino)- β -D-xylo-hexopyranosyl]oxy]-
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677727-79-6 HCAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[3-1-[(5R)-3-
(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
yl]propyl]amino)- β -D-xylo-hexopyranosyl]oxy]-
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-80-9 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(4-
 dimethylamino)-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-
 triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-81-0 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3-
 fluoro-4-((2-hydroxyethyl)methylamino)phenyl]-2-oxo-5-oxazolidinyl)methyl]-
 1H-1,2,3-triazol-4-yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-82-1 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3,5-
 difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677727-83-2 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[(3-[1-[(5R)-3-(3,4-
 dichlorophenyl)-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-
 yl]propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-84-3 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[1-[(5R)-3-(2-
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-85-4 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[1-[(5R)-3-(3-
 fluoro-4-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-86-5 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[1-[(5R)-3-(4-
 fluoro-3-methylphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-87-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[2-[1-[(5R)-3-(4-
 hydroxypropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-88-7 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-
 hydroxyethyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-89-8 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-
 hydroxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-90-1 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-
 hydroxypropyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-91-2 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl)methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-92-3 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3,4-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-93-4 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-[2-
 fluoro-4-[(4-quinolylmethyl)amino]methyl]-1,1'-biphenyl]-4-yl)-2-oxo-5-
 oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)ethyl]methylamino]-β-D-
 xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-94-5 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3,5-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677727-95-6 HCAPIUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-1-[(5R)-3-(3,5-
 difluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-96-7 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[[2-1-[(5R)-3-(3-
 fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)ethoxy]carbonylmethylamino]-β-D-xylo-hexopyranosyl]oxy]-
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-97-8 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[[2-1-[(5R)-3-(3-
 fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)ethoxy]carbonylmethylamino]-β-D-xylo-hexopyranosyl]oxy]-
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-98-9 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[[2-1-[(5R)-3-(4-
 [(dimethylamino)sulfonyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677727-99-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[[2-1-[(5R)-3-(4-
 [(dimethylamino)sulfonyl]phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl)propyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677728-00-6 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[(1-[(5R)-3-(3-chloro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl)-1H-1,2,3-triazol-4-yl]ethyl)amino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-1-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677728-01-7 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 11-[(3-[(2-[(1-[(5R)-3-cyclopentyl-2-oxo-5-oxazolidinyl]methyl)-1H-1,2,3-triazol-4-yl]ethyl)amino]-3,4,6-trideoxy- β -D-xylo-hexopyranosyl)oxy]-13-[(2,6-dideoxy-3-C-methyl-1-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677728-02-8 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl(2-[(1-[(5R)-2-oxo-3-(4-(trifluoromethyl)phenyl)-5-oxazolidinyl]methyl)-1H-1,2,3-triazol-4-yl]ethyl)amino]- β -D-xylo-hexopyranosyl)oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 677728-03-9 HCAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[methyl(2-[(1-[(5R)-2-oxo-3-(4-(trifluoromethyl)phenyl)-5-oxazolidinyl]methyl)-1H-1,2,3-triazol-4-yl]ethyl)amino]- β -D-xylo-hexopyranosyl)oxy]- (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 677728-04-0 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(3-
 fluoro-4-methoxyphenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B





RN 677729-42-9 HCPLUS
 CN Erythromycin, N-demethyl-N-[2-[1-[(5R)-3-[2-fluoro-4'-
 (hydroxymethyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-
 triazol-4-yl]ethyl]-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-B




PAGE 2-A



RN 678182-71-3 HCPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-[(2-[(1-[(5R)-3-(trans-
 4-hydroxycyclohexyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-
 yl)ethyl]methylamino)-β-D-xylo-hexopyranosyl]oxy]-
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ED Entered STN: 22 Feb 2004
 GI



AB Antibacterial agents of formula I [A = 2-oxazolidinone, isoxazoline, furanone, etc.; X, Y = CO, (substituted) NH; R = acylamino, heterocyclo, etc.; R1-R3 = H, halo, Me; R4 = H, alkyl, alkoxy, alkylthio, alkylamino] are prepared. Thus, II was prepared and had MIC of 1 μ g/mL.

ACCESSION NUMBER: 2004143139 HCAPLUS

DOCUMENT NUMBER: 140:181437

TITLE: Preparation of N-aryl-2-oxazolidinones and their derivatives as antibacterial agents

INVENTOR(S): Goodwood, Robert C.; Ochoada, Jason M.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014897	A1	20040219	WO 2003-US22486	20030801
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PG, PT, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KS, LS, MW, MZ, SD, SW, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CL, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2491287	A1	20040219	CA 2003-2491287	20030801
US 2004072873	A1	20040415	US 2003-632742	20030801
EP 1539745	A1	20050615	EP 2003-784775	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013400	A	20050712	BR 2003-13400	20030801
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 140:181437				
IT 658073-58-6P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ED Entered STN: 26 Jan 2004

GI



AB Title compds. I [wherein R1 = H, (un)substituted (cyclo)alkyl, (un)substituted alkanoyl, acylmercapto, heterocyclylcarbonyl, etc.; R2, R3, R4 = H, halogen; R4 = alkylsulfonyl, (un)substituted alkylthiocarbonylamino, (un)substituted ureido, carbamato, etc.; A, B = independently selected from H, alkyl, CO₂Et, halogen and salts or solvates thereof] were prepared as antibacterial agents. For example, reaction of (S)-N-[3-(4-(4-cyanomethylidene)piperidin-1-yl)-3-fluorophenyl]-2-oxazolidinyl-5-ylmethyl]amine with carbon disulfide (69%), followed by addition of sodium methoxide, gave II in 77% yield. II showed 1.56-6.25 μ g/mL (MIC) against linezolid resistant strains, such as S. aureus MRSA-32, S. pneumoniae SPN744 and E. faecium 367, 0.2 μ g/mL (MIC) against linezolid sensitive strains, such as S. aureus MRSA-32 and S. pneumoniae 49619, 1.56 (MPC) for the treatment of E. faecalis 416 infection, and etc. 3D quant. structure activity relationship (3D-QSAR) showed that the steric contributions of I are over one and half times more than the electrostatic contributions, compared to literature compds. Thus, I and their pharmaceutical compds. targeting multiple ribonucleoprotein sites are useful as antimicrobial agents for treating bacterial infections.

ACCESSION NUMBER: 2004:60503 HCAPLUS

DOCUMENT NUMBER: 140:128407

TITLE: Preparation of (piperidinophenyl)oxazolidinones targeting multiple ribonucleoprotein sites as antibacterial agents

INVENTOR(S): Patel, Mahesh V.; Deshpande, Prasad K.; Sindhkhad, Milind D.; Gupke, Shrikant V.; Chugh, Yati; Shetty, Nitin; Shukla, Milind C.; Yeola, Ravindra D.; De Souza, Noel J.

PATENT ASSIGNEE(S): India
 SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007499	A2	20040122	WO 2003-IN238	20030710
WO 2004007489	A3	20040318		

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, FI, GB, GD, GE, GH,

L12 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 658073-58-6 HCAPLUS
 CN 2-Piperidinone, 5-[2,6-difluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CH, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

CA 2492194 AA 20040122 CA 2003-2492194 20030710

EP 1565461 A2 20050824 EP 2003-753912 20030710

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-395164P P 20020711
 WO 2003-IN238 W 20030710

OTHER SOURCE(S): MARPAT 140:128407

IT 648918-90-5P 648918-10-2P 648918-12-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 648918-90-5 HCAPLUS


CN 1H-1,2,3-Triazolo-4-carboxylic acid, 1-[(5R)-3-[4-(4-cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinylmethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648918-10-2 HCAPLUS
 CN 1H-1,2,3-Triazolo-4-carboxylic acid, 1-[(5R)-3-[4-(4-cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinylmethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648919-12-4 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5R)-3-[(4-(cyanomethylene)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 648918-91-6P 648919-11-3P 648920-06-3P
 648920-10-9P 648920-11-0P 648920-33-6P
 648920-34-7P 648920-35-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 648918-91-6 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5R)-3-[(4-(cyanomethylene)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 648919-11-3 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[(5R)-3-[(4-(cyanomethylene)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



RN 648920-10-9 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5R)-3-[(4-(cyanomethyl)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 2-A


RN 648920-06-3 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[(4-(cyanomethyl)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-11-0 HCAPLUS
 CN 4-Piperidinoneacetonitrile, 1-[(5R)-3-[(4-(cyanomethyl)-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-33-6 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-34-7 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 648921-31-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)
 RN 648921-31-7 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 648921-09-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)
 RN 648921-09-9 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-35-8 HCAPLUS
 CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 30 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Nov 2003
GI



AB The title compds. [I; R1-R5 = H, halo, (un)substituted alkoxy, Q = halo, OH, NH₂, N₃, each (un)substituted Cl-8 alkoxyl, Cl-8 alkylsulfonyl, Cl-8 alkylsulfonyl, mono- or di(C1-8 alkyl)amino, Cl-8 alkylcarbonyl, C3-8 cycloalkenylcarbonylamin, monocyclic (un)saturated heterocycliccarbonylamin, Cl-8 alkylcarbonylamin, tri(C1-8 alkyl)silyl, or N-C1-8 alkyl-N-C1-8 alkylcarbonylamin] or pharmaco., acceptable salts thereof or hydrates thereof are prepared. These compds. [I] possess antibacterial activity against sensitive bacteria on which existing drugs are effective as well as multidrug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and Penicillin-resistant *Streptococcus pneumoniae* (PRSP). Thus, 7.5 μ L Et dithioacetate was added to a solution of 15.1 mg 4-[(5S)-5-acetamidomethyl-2-oxazolidin-3-yl]-[4'-(5S)-5-amino-2-oxazolidin-3-yl]-2,2'-difluorobiphenyl (preparation given) in 0.5 mL DMF and stirred at room temperature for 14 h to give 80.4 mg 4-[(5S)-5-acetamidomethyl-2-oxazolidin-3-yl]-4'-(5S)-5-thiocetamidomethyl-2-oxazolidin-3-yl]-2,2'-difluorobiphenyl (II). II showed min. inhibitory concentration of 0.125 μ g/mL against MRSA and vancomycin-resistant *Enterococcus faecium*.

ACCESSION NUMBER: 2003:929941 HCPLUS

DOCUMENT NUMBER: 140:5040

TITLE: Preparation of bis(2-oxazolidin-3-yl)biphenyl derivatives as antibacterial agents

INVENTOR(S): Shikawa, Sojirō; Ishikawa, Makoto; Yanagisawa, Yukiko; Kawaguchi, Masami; Maehashi, Kazunori; Yoshida, Satoshi

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

SOURCE: JPO/KAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335762	A2	20031128	JP 2002-144414	20020520
PRIORITY APPLN. INFO.:			JP 2002-144414	20020520
OTHER SOURCE(S):	MARPAT	140:5040		

IT 627542-99-SP
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L12 ANSWER 30 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

(Uses)
(prepn. of bisoxazolidinyl)biphenyl derivs. as antibacterial agents)
RN 627542-99-8 HCPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-[(5S)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl-1[1',1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl-1]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 627543-24-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Preparation or reagent)
(prepn. of bisoxazolidinyl)biphenyl derivs. as antibacterial agents)
RN 627543-24-2 HCPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)- (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 31 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 05 Sep 2003

GI



AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as e.g., (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-acidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-triazol-2-yl wherein R1 is, for example, halo or (1-4C)alkyl that is substituted by 1 substituent, for example, OH, (1-4C)alkoxy, amino, cyano, azid, Q = for example, 3-R2-1-5-R3phenyl wherein R2 and R3 = H or fluoro, T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S) are useful as antibacterial agents, and processes for their manufacture and pharmaceutical compns. containing them are described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concn. of II against methicillin sensitive and quinolone sensitive *Staphylococcus aureus* and against methicillin resistant and quinolone resistant *Staphylococcus aureus* are 1 and 8 μ g/mL, resp. Compds. I show a favorable decreased MAC-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted acylmethyl or hydroxymethyl. They also showed favorable decreased HAO-A potency compared with analogs in which the HET group is unsubstituted. Sixty-one example preps. of I are included. For example, to prepare II, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (2.7 mmol) (preparation given) was suspended in CH₂Cl₂ (10 mL), 1,9-diazabicyclo[5.4.0]undec-7-ene (4.7 mmol) was added and the reaction mixture was cooled to -5°, diphenylphosphoryl azide (3.25 mmol) was added dropwise and it was stirred for 16 h at room temperature, workup gave 1.02 g of II.

ACCESSION NUMBER: 2003:696895 HCPLUS

DOCUMENT NUMBER: 139:214459

TITLE: Preparation of 5-acylmethyl oxazolidinones and their use as antibacterial agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert

PATENT ASSIGNEE(S): AstraZeneca AB, Sweden; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 126 pp.

L12 ANSWER 31 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072576	A2	20030904	WO 2003-GB791	20030225
WO 2003072576	A3	20031231		

W: AB, AG, AL, AM, AT, AU, BR, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GI, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SL, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, SD, SL, S2, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CG, CI, GA, GU, GW, HL, MR, NE, SN, TD, TG

CA 2477379 AA 20030904 CA 2003-2477379 20030225

EP 1480975 A2 20041201 EP 2003-742987 20030225

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003080018 A 20050104 BR 2003-8018 20030225

US 2005182112 A1 20050818 US 2003-505902 20030225

JP 2003513504 T2 20051020 JP 2003-571282 20030225

PRIORITY APPLN. INFO.: WO 2002-360688P P 20020228


OTHER SOURCE(S): MARPAT 139:214459 WO 2003-GB791 20030225

IT 591253-17-7W, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methoxycarbonyl)-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-18-8W, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-acidomethyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-19-9W, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-23-5W, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-aminomethyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-26-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-27-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-bromomethyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one 591253-30-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-31-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-32-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-33-7W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-34-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-35-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-36-0W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-37-1W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-38-2W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-39-3W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-40-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-41-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-42-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-43-7W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-44-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-45-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-46-0W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-47-1W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-48-2W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-49-3W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-50-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-51-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-52-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-53-7W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-54-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-55-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-56-0W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-57-1W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-58-2W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-59-3W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-60-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-61-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-62-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-63-7W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-64-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-65-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-66-0W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-67-1W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-68-2W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-69-3W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-70-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-71-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-72-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-73-7W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-74-8W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-75-9W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-76-0W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-77-1W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-78-2W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-79-3W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-80-4W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-81-5W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxazolidin-2-one 591253-82-6W, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]methyl)methyl]oxaz

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 591253-98-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one, 591254-03-4P, (5R)-3-[(4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl)-5-[(4-(2-hydroxyethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (drug candidate; prepns. of 5-oxolymethyl oxazolidinones and their use as antibacterial agents)

RN 591253-17-7 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-18-8 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(azidomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-19-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-23-5 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 591253-26-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591253-27-9 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(bromomethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591253-30-4 HCAPLUS
 CN Carbaminidothiolic acid, [1-[(5R)-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-31-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(methylthio)methyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-34-8 HCAPLUS
 CN Phosphoric acid, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-50-8 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-54-2 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(2,2-dibromoethenyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-69-9 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-amino-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-75-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethoxy-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-77-9 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-bromo-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-84-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(2-propynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-98-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591254-03-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591253-16-69, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-cyano-1,2,3-triazol-1-yl]oxazolidin-2-one 591253-20-29, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(5-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-21-39, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-trifluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-22-49, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[5-trifluoromethyl-1,2,3-triazol-1-yl]oxazolidin-2-one 591253-24-69, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(aminocarbonyl)-1,2,3-triazol-1-yl]oxazolidin-2-one 591253-25-79, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(methoxycarbonyl)amino]methyl]-1,2,3-triazol-1-yl]oxazolidin-2-one 591253-28-09, (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-morpholinyl)-2-butyanyl]-1,2,3-triazol-1-yl]oxazolidin-2-one 591253-32-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(methylsulfonyl)methyl]-1,2,3-triazol-1-yl]oxazolidin-2-one


L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
591253-36-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(cyanomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-38-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-chloromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-40-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-hydromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-42-89, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-((1H-1,2,3-triazol-4-yl)thiomethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-44-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-((1H-imidazol-2-yl)thiomethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-46-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-((phenylmethyl)thiomethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-48-49, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(difluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-52-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-difluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-56-49, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(2-bromoethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-62-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(2-bromomethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-64-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(dimethylamino)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-65-59, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-[(ethylamino)carbonyl]methyl]-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-67-79, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(2-(dimethylamino)-2-oxoethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-74-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-((ethylamino)carbonyl)methyl]-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-78-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(chloro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-81-59, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(fluoro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-82-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(fluoro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-83-79, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(3-hydroxy-1-propynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-86-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-87-19, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one trifluoroacetate 591253-88-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(5-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-89-39, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-90-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-dimethylamino-2-butynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one trifluoroacetate

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
591253-91-79, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-[(4-methyl-1-phenyl)-2-butyanyl]-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-92-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-morpholinyl)-2-butyanyl]-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-93-99, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(3-fluorophenyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one trifluoroacetate 591253-94-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-ethynyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-96-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-hydroxy-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591253-97-39, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-[(4-methyl-1-phenyl)-2-butyanyl]-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-00-19, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(5-difluorophenyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-01-29, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-methylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-02-59, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(cyclopoly-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-04-59, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-fluoromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-05-69, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-ethenyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-06-79, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-methoxymethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-07-89, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-chloromethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-08-99, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-ethynyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-09-09, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(5-difluorophenyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-10-39, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-methylthio-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-11-49, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(2-chloroethyl)-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591254-12-59, (5R)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(4-nitro-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-16-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 591253-20-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-21-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-22-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-24-6 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-25-7 HCAPLUS
 CN Carbamic acid, [(1-[(5R)-3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl)-1H-1,2,3-triazol-4-yl)methyl]methyl ester, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-28-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-32-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-[(methylsulfonyl)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-36-0 HCAPLUS
 CN 1H-1,2,3-Triazole-4-acetonitrile, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-38-2 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(chloromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-40-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-42-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[(1H-1,2,3-triazol-4-ylthio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-44-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[(1H-imidazol-2-ylthio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-46-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[(phenylmethyl)thio)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-48-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-52-0 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-56-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[(3-methyl-5-isoxazolyl)ethynyl]-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-58-6 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-[(3-butyl-1-ynyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-60-0 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-[(1E)-2-bromoethenyl]-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 591253-62-2 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4-(bromothiophenyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-64-4 HCAPIUS
 CN 1H-1,2,3-Triazole-4-acetamide, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-65-5 HCAPIUS
 CN 1H-1,2,3-Triazole-4-acetamide, 1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-67-7 HCAPIUS
 CN Carbamic acid, ethyl-, [1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-Triazol-4-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-74-6 HCAPIUS
 CN Acetamide, N-[1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-78-0 HCAPIUS
 CN 2-Oxazolidinone, 5-[(4-chloro-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-81-5 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-82-6 HCAPIUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(5-fluoro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-83-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(3-hydroxy-1-propynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-86-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(dimethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-87-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(dimethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 591253-86-0
 CMF C23 H26 F NS O4 S

Absolute stereochemistry.




CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 591253-88-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(5-hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-89-3 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(diethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-90-6 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(diethylamino)-2-butynyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 591253-89-3
 CMF C25 H30 F NS O4 S

Absolute stereochemistry.




CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 591253-91-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-(2,5-dihydro-1H-pyrrol-1-yl)-2-butynyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591253-92-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[4-(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-93-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-[4-(4-morpholinyl)-2-butynyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 591253-92-8
 CNF C25 H28 F N5 O5 S

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CNF C2 H F3 O2




RN 591253-94-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-ethynyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-96-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-hydroxy-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591253-97-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-00-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl)-5-[(4-(methylthio)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-01-2 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-cyclopropyl-1H-1,2,3-triazol-1-yl)methyl]-3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-04-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-ethenyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-05-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-(methoxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-06-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(5-(methoxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-07-8 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(chloromethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-08-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-(2-chloroethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-09-0 HCAPLUS
 CN Carbamic acid, [(1-[(5R)-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-10-3 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-(2-chloroethyl)-1H-1,2,3-triazol-1-yl)methyl]-3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591254-11-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-nitro-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-62-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-91-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 one 591231-95-7P, (SR)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-butyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-97-9P, (SR)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-00-7P, (SR)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-02-9P, (SR)-3-[4-(1,1-Dioxo-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-03-0P, (SR)-3-[3,5-Difluoro-4-(1-oxo-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-06-0P, (SR)-3-[4-(1,1-Dioxo-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-11-0P, (SR)-3-[4-(1,1-Dioxo-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-12-1P, (SR)-3-[4-(1,1-Dioxo-2,5-dihydrothien-3-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-13-2P, (SR)-3-[3-Fluoro-4-(4-bromo-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-16-4P, (SR)-3-[3-Fluoro-4-(4-methyl-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-23-9P, (SR)-3-[3-Fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-24-1P, (SR)-3-[3-Fluoro-4-[(hydroxymethyl)methylimidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-42-7P, (SR)-3-[3-Fluoro-4-(4-formimidazol-1-yl)phenyl]-5-[(4-pentyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-46-0P, (SR)-3-[3-Fluoro-4-(hydroxymethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-46-1P, (SR)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-49-4P, (SR)-3-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-50-7P, (SR)-3-[3-Fluoro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-58-5P, (SR)-3-[3-Fluoro-4-(trans-1-methoxytetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-60-9P, (SR)-3-[3-Fluoro-4-(cis-1-methoxytetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-68-7P, (SR)-3-[4-(1,1-Dioxotetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-69-8P, (SR)-3-[3,5-Difluoro-4-(trans-1-methoxytetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-70-1P, (SR)-3-[3,5-Difluoro-4-(cis-1-methoxytetrahydro-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-88-1P, (SR)-3-[3,5-Difluoro-4-(1-glycolyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-93-9P, (SR)-3-[4-(1-[(2S)-2,3-Dihydroxyprop酰]1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-98-0P, (SR)-3-[3-Fluoro-4-(1-glycolyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-98-1P, (SR)-3-[3-Fluoro-4-(1-glycolyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-77-5 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)




RN 591232-96-1 HCAPLUS
 CN Pyridine, 1-[(acetyl oxy)acetyl]-4-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 591231-77-5P, (SR)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-84-4P, (SR)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-isopropyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591231-90-2P, (SR)-3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-

Absolute stereochemistry.




RN 591231-84-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591231-90-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591231-95-7 HCAPLUS
 CN 2-Oxazolidinone, 5-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-3-(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591231-97-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-ethyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-00-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-02-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-03-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-09-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-11-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-12-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(2,5-dihydro-1,1-dioxido-3-thienyl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-13-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-15-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-23-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-46-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-49-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-50-7 HCAPLUS
 CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-31-4 HCAPLUS
 CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute Stereochemistry.
 Double bond geometry unknown.




RN 591232-42-7 HCAPLUS
 CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-[(4-pentyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-43-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-hydromethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-58-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-60-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-69-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-69-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-70-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-88-1 HCAPLUS
 CN Pyridine, 4-[2,6-difluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-93-8 HCAPLUS
 CN Pyridine, 4-[2,6-difluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-95-0 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 591232-98-3P, (5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SFN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PRMP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-98-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-98-6P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 501940-28-9P,


L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (SR)-3-(3-Fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one 591232-44-9P, (SR)-3-4-[(4-[(tert-Butyldimethylsilyl)oxy]methyl)-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one 591232-89-2P, (SR)-3-4-[(1-Acetoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one 591232-50-5P, (SR)-3-[3-(3,5-Difluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one hydrochloride 591232-94-9P, (SR)-3-4-[(1-((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one 591232-97-2P, (SR)-3-[3-(3-Fluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one monohydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyclol (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 501939-98-6 HCAPLUS

CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 501940-28-9 HCAPLUS

CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RL: HCl

CN Pyridine, 4-[(2,6-difluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl)-1-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-94-9 HCAPLUS
 CN Pyridine, 4-[(2,6-difluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl)-1-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 591232-44-9 HCAPLUS
 2-Oxazolidinone, 3-[(4-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591232-89-2 HCAPLUS

CN Pyridine, 1-[(acetyl)acetyl]-4-[2,6-difluoro-4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591232-90-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-Difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, hydrochloride, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 591231-82-2P, (SR)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidin-2-one
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of cyclol (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591231-82-2 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(5-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. I (R1 = H, halo, alkyl, or haloalkyl; R2 = morpholinyl, piperidinyl or its derivative, or 4-substituted piperazinyl; R3 = OH, SH, acylony, sulfonylony, acylamino, diacylimino, pentabasic heterocyclic group or its deriv., and when R1 = F, R2 or R3 = morpholinyl or acetamido), useful as antibacterial agents against Gram-pos. bacteria, are prepared. For example, (R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone was converted to mesylate, condensed with potassium phthalimide, and treated with aqueous MeNH2 to give the bactericide linezolid.

ACCESSION NUMBER: 2003:576097 HCAPLUS

DOCUMENT NUMBER: 139:85332

TITLE: Preparation of oxazolidinone derivatives as antibacterial agents

INVENTOR(S): Liu, Jun; Meng, Qingguo; Jin, Jie; Wu, Yanbin
PATENT ASSIGNEE(S): Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 50 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Chinese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1355165	A	20020626	CN 2001-144613	20011219
PRIORITY APPLN. INFO.:		CN 2001-144613 20011219		
OTHER SOURCE(S):	CASREACT 139:85332; MARPAT 139:85332			

IT 556801-07-1
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinone derivs. as antibacterial agents)
RN 556801-07-1 HCAPLUS
CN 2-Oxazolidinone, 5-(1H-benzotriazol-1-ylmethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB PH-027 is a new 5-triazole oxazolidinone synthesized that shows strong activity against Gram-pos. aerobic bacteria, including clin. isolates. The objective of this study was to investigate the in vitro activity of this compound in comparison with linezolid and other antibiotics against Gram-pos. and Gram-neg. anaerobes. The in vitro activity of PH-027 in comparison with those of linezolid and other antimicrobial agents was evaluated against 201 clin. isolates of Gram-pos. and Gram-neg. anaerobic bacteria by agar dilution and Etest methods. PH-027 showed excellent activity, with min. inhibitory concns. (MIC) in the range of 0.12-4.0 μ g/mL against all isolates, MIC90s being 4.0, 1.0, 2.0, 2.0 and 2.0 μ g/mL against Clostridium difficile, Peptostreptococcus spp., Bacteroides fragilis, Prevotella bivia and Fusobacterium spp. resp. In comparison, linezolid had MIC in the range of 0.5-4.0 μ g/mL against all isolates, with MIC90s of 2.0, 4.0, 4.0 and 2.0 μ g/mL against the same set of bacteria resp. PH-027 demonstrated excellent in vitro activity that is superior to linezolid against Peptostreptococcus spp., B. fragilis and P. bivia. However, against C. difficile and Fusobacterium spp., PH-027 and linezolid showed comparable in vitro activity. Against all anaerobes, metronidazole, PH-027 and, to a lesser extent, linezolid had the most potent activity. From the results of in vitro susceptibility testing, both linezolid and PH-027 show promise in the treatment of anaerobic infections.

ACCESSION NUMBER: 2003:471767 HCAPLUS

DOCUMENT NUMBER: 139:49714

TITLE: Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria

AUTHOR(S): Phillips, O. A.; Rotimi, V. O.; Jamal, W. Y.; Shahin, M.; Vergheese, T. L.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Kuwait

SOURCE: Journal of Chemotherapy (Firenze, Italy) (2003), 15(2), 113-117

CODEN: JCHEEU; ISSN: 1120-009X

PUBLISHER: E.I.F.T. srl

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 503090-32-2, PH 027

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(comparative in vitro activity of PH-027 vs. other antimicrobials against clin. isolates of Clostridium difficile and other anaerobic bacteria)

RN 503090-32-2 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 35 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 543682-54-8 HCPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(SR)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-55-9 HCPLUS
 CN Cyclopropanecarbonitrile, 1-[2-fluoro-4-[(SR)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-64-0 HCPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(SR)-5-[(5-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 543682-65-1 HCPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(SR)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-66-2 HCPLUS
 CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(SR)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 35 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 543682-67-3 HCPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(SR)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543682-68-4 HCPLUS
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(SR)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543682-69-5 HCPLUS


L12 ANSWER 35 OF 41 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-1,2,3-Triazole-4-carboxamide, 1-[(SR)-3-[4-(1-cyanocyclopropyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-70-8 HCPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(SR)-5-[(4-formyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-71-9 HCPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(SR)-5-[(4-(hydroxymethyl)methyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 543682-72-0 HCAPLUS
 CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[(5R)-3-[(4-(1-cyanocyclopropyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-73-1 HCAPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-[(methoxymino)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 543682-74-2 HCAPLUS
 CN Cyclopropanecarbonitrile, 1-[(5R)-5-[(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-76-4 HCAPLUS
 CN Acetamide, N-[(1-[(5R)-3-[(4-(1-cyanocyclopropyl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543682-77-5 HCAPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[(5R)-5-[(4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 543683-87-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of chiral cyclopropylphenyloxazolidinones as antibiotics)
 RN 543683-57-4 HCAPLUS
 CN Cyclopropanecarbonitrile, 1-[2-methyl-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. I [wherein HET = (un)substituted 5-membered heterocyclic or 6-membered dihydroheteroaryl ring containing heteroatoms selected from N, O, and S; Q = Q1, Q2, etc.; R2 and R3 = independently H or F; T = (un)substituted C-linked 5-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; preferably 1 (un)substituted 1,3,4-thiadiazolyl, thiadiazolyl, 1,3,4-oxadiazolyl, or oxadiazolyl] and a pharmaceutically acceptable salt or hydrolyzable esters thereof] were prepared as antibacterial agents. For example, (5R)-3-(3-fluoro-4-(1-iodophenyl)-5-hydroxymethyl)-1,3-oxazolidin-2-one was mesylated and the product converted to the azide. Cyclization of the azide with bicyclo[2.2.1]heptadiene gave the 1,2,3-triazole, which was substituted with hexamethylditin to afford the stannane. Reaction with 5-chloro-1,3,4-thiadiazole-2-carbonitrile in the presence of AsPh₃ and tri(diphenylidenecarbonato)dipalladium in N-methyl-2-pyridolinone provided II. The latter inhibited bacterial growth against *Staphylococcus aureus* (methicillin sensitive and quinolone sensitive), *Staphylococcus aureus* (methicillin resistant and quinolone resistant), *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae* and *Moraxella catarrhalis* with MIC values of 0.125 µg/mL, 0.25 µg/mL, 0.125 µg/mL, 0.125 µg/mL, 2 µg/mL, and 0.5 µg/mL, resp.

ACCESSION NUMBER: 20031335104 HCAPLUS

DOCUMENT NUMBER: 1391353972

TITLE: Preparation of 3-aryloxazolidinones with antibacterial activity

INVENTOR(S): Gravestock, Michael Barry


PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXX02


DOCUMENT TYPE: Patent

LANGUAGE: English




RN 519003-02-2 HCAPLUS
CN 1,3,4-Thiadiazole-2-carboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-03-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(5-(aminomethyl)-2-thiazolyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-05-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035648	A1	20030501	WO 2002-GB4796	20021023
W: AZ, AG, AL, AW, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TV, TM, TN, TR, TT, TZ, UA, UG, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2396350	A1	20040623	GB 2004-8399	20021023
EP 1446403	A1	20040818	EP 2002-770098	20021023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TH, BG, CZ, EE, SK				
JP 2005519870	T2	20050707	JP 2003-538164	20021023
US 2005043374	A1	20050224	US 2004-493609	20041018
PRIORITY APPLN. INFO.:			US 2001-330589P	P 20011025
			WO 2002-GB4796	W 20021023

OTHER SOURCE(S): MARPAT 138:353972
IT 519003-00-0P, (5R)-3-[3-Fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-02-2P, (5R)-3-[3-Fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-03-2P, (5R)-3-[4-(5-(Methylsulfonyl)-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-05-5P, (5R)-3-[2-Fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-11-3P, (5R)-3-[3-Fluoro-4-(4-methyl-1,3,4-thiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-14-6P, (5R)-3-[3-Fluoro-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
519003-16-8P, (5R)-3-[3-Fluoro-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one

RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); B10L (Biological study); PMP (Preparation); USES (Use); (Antibacterial agent; preparation of (aryl)oxazolidinones as antibacterial agents)


RN 519003-00-0 HCAPLUS
CN 1,3,4-Thiadiazole-2-carbonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-11-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-14-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(trifluoromethyl)-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-16-8 HCAPLUS
CN 1,3,4-Thiadiazole-2-acetonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-94-2P, (5R)-3-(3-Fluoro-4-(trimethylstannyl)phenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-94-3P, (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-06-9P, 2-Fluoro-N'-acetyl-4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-3-yl]benzohydrazide 519003-07-7P 519003-08-8P 519003-12-4P 519003-13-5P 519003-15-7P 519003-17-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (Intermediate) preparation of (aryl)oxazolidinones as antibacterial agents)

RN 501939-94-2 HCAPLUS


CN 2-Oxazolidinone, 3-(3-fluoro-4-(trimethylstannyl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-95-3 HCAPLUS
CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-06-6 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 2-acetylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-07-7 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-08-8 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-12-4 HCAPLUS
CN Benzenecarbothioamide, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 519003-13-5 HCAPLUS
CN Benzamide, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-

Absolute stereochemistry.




RN 519003-15-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-17-9 HCAPLUS
CN Benzoic acid, 2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]-, 2-(cyanoacetyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 21 Mar 2003
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones and isoxazolines (shown as I; variables defined below, e.g. (5S,5S')-N-[3-(4'-(5-(acetylaminomethyl)-2-oxoisoazolidin-3-yl)-2,2'-difluorobiphenyl-4-yl)-2-oxoisoazolidin-5-ylmethyl]acetamide (shown as II)), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manufacture and pharmaceutical compns. containing them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxoisoazolidin-3-yl-2-isoxazolin-3-yl; R₂ to R₆ = H and R_{1a} and R_{1b} =, for example, hydroxy, -NH(R₄), NH(HET-1) and HET-2, wherein V is O or S; R₄ is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens, including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 µg/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prepared as follows: (5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxoisoazolidin-5-ylmethyl]acetamide (0.4 mmol) and Bu₄NBr (0.4 mmol) were stirred in a mixture of DMF (0.5 mL) and NtBu₃ (2 mmol), and degassed by bubbling N₂. Pd(II) acetate (0.04 mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are tabulated:


ACCESSION NUMBER: 2003:221667 HCAPLUS
 DOCUMENT NUMBER: 138:238171
 TITLE: Preparation of oxazolidinones and/or isoxazolines as antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXDD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200302824	A1	20030320	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2459766 AA 20030320 CA 2002-2459766 20020909
 EP 1427711 A1 20040616 EP 2002-765019 20020909
 EP 1427711 B1 20050713
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002012458 A 20041019 BR 2002-12458 20020909
 JP 2005S07396 T2 JP 2003-526899 20020909
 US 2005107435 A1 20050519 US 2003-489266 20020909
 NZ 531621 A 20050624 NZ 2002-531621 20020909
 AT 299502 E 20050715 AT 2002-765019 20020909
 2A 2004001888 A 20050418 2A 2004-1888 20040308
 NO 2004001428 A 20040608 NO 2004-1428 20040405
 GB 2001-21942 A 20010911
 GB 2002-15420 A 20020704
 W 2002-GB4120 W 20020909
 PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 138:238171
 IT 501940-31-4P, (SR)-5-[(tert-Butyldimethylsilyl)oxy]methyl]-3-[4'-(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl-1,1'-biphenyl-4-yl]-3-oxazolidin-2-one 501940-39-2P,
 (SR)-3-[4'-(5-[(tert-Butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl]-3-[4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-43-8P, (SR)-3-[4'-(5-[(tert-Butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl]-3-oxazolidin-2-one
 RL: PAC (Pharmacological activity); ACT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses);
 (d) candidate preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
 RN 501940-31-4 HCAPLUS
 CN 2-Oxazolidinone, 5-[(1,1-dimethylethylidimethylsilyl)oxy]methyl]-3-[4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-2-oxo-3-oxazolidinyl-1,1'-biphenyl]-4-yl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-39-2 HCAPLUS

Page 15329/11/2005

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 2-Oxazolidinone, 3-[4'-(5-[(1,1-dimethylsilyl)oxy]methyl)-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 501940-43-8 HCAPLUS

CN 2-Oxazolidinone, 3-[4'-(5-[(1,1-dimethylsilyl)oxy]methyl)-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-93-1P, (5R,5'R)-4,4'-Bis[5-(1H-1,2,3-triazol-1-yl)methyl-2-oxoisoazolidin-3-yl]-2,2'-difluorobiphenyl 501939-96-4P,
 (5R)-3-(2-Fluoro-4-[(5-hydroxymethyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-04-1P, N-[(3-(2,2'-difluoro-4-[(5-hydroxymethyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-11-0P,
 (5R)-3-[2,2'-difluoro-4-[(5-hydroxymethyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-12-1P, (SR)-3-[2,2'-difluoro-4-[(5-hydroxymethyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-26-7P,
 (5R,5'R)-3-[2,2'-difluoro-4-[(5-hydroxymethyl)-4,5-dihydroisoazol-3-yl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl]-2-




RN 501940-37-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-39-1 HCAPLUS
 CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4'-(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-41-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-42-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-46-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-48-3 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-59-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-74-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[5-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-thienyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-76-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[5-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-thienyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 501939-69-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(5-bromo-2-pyridinyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-70-4 HCAPLUS
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-73-7 HCAPLUS
 CN 2-Oxazolidinone, 3-(4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 501940-19-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[(1,1-dimethylethyl)dimethylsilyloxy]methyl)-4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-20-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[(1,1-dimethylethyl)dimethylsilyloxy]methyl)-4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-27-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-(trimethylstannyl)phenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 501939-94-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[(3-fluoro-4-(trimethylstannyl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-98-6 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 501940-19-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-[(1,1-dimethylethyl)dimethylsilyloxy]methyl)-4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501940-28-9 HCAPLUS
 CN 2-Oxazolidinone, 3-(3-fluorophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 03 Dec 2002

AB A series of 5-substituted oxazolidinones with varying substitution at the 5-position of the oxazolidinone ring were synthesized and their in vitro antibacterial activity was evaluated. The compds. demonstrated potent to weak antibacterial activity. A novel compound (PH-027) demonstrated potent antibacterial activity, which is comparable to or better than those of linezolid and vancomycin against antibiotic-susceptible standard and clin. isolated resistant strains of gram-pos. bacteria. Although the presence of the C-5-acetamidomethyl functionality at the C-5 position of the oxazolidinone has been widely claimed and reported as a structural requirement for optimal antimicrobial activity in the oxazolidinone class of compds., our results from this work identified the C-5 triazole substitution as a new structural alternative for potent antibacterial activity in the oxazolidinone class.

ACCESSION NUMBER: 2002-915641 HCAPLUS

DOCUMENT NUMBER: 138:268234

TITLE: Synthesis and antibacterial activity of 5-substituted oxazolidinones

AUTHOR(S): Phillips, O. A.; Udo, E. E.; Ali, A. A. M.; Al-Hassavi, N.

CORPORATE SOURCE: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kuwait University, Safat, 13110, Kuwait

SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(1), 35-41

CODEN: BMCECP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:268234


IT 503026-28-3P

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of 5-substituted oxazolidinones)

RN 503026-28-3 HCAPLUS

CN 2-Oxazolidinone, 5-[(4-acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of 5-substituted oxazolidinones)

RN 503026-26-4 HCAPLUS

CN 2-Oxazolidinone, 5-[(5-acetyl-1H-1,2,3-triazol-1-yl)methyl]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 503026-28-6P 503026-29-7P

RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation) (synthesis and antibacterial activity of 5-substituted oxazolidinones)

RN 503026-28-6 HCAPLUS

CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 503026-27-5P 503090-32-2P, PH 027

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antibacterial activity of 5-substituted oxazolidinones)

RN 503026-27-5 HCAPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-[(4-[1-(methoxymido)ethyl]-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 503090-32-2 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 503026-26-4P

L12 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 503026-29-7 HCAPLUS

CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[(5R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [1; HET = N-linked 5-membered, fully or partially unsatd. heterocyclic ring, or an N-linked 6-membered di-hydro-heteroaryl ring; Q = II, III, etc. (wherein R2, R3 = H, F; T = IV, V, etc.)] and their pharmaceutically-acceptable salts, useful in production of an antibacterial effect in a warm blooded animal, were prepared. E.g., detailed multi-step synthesis of (5R)-VI as its mesitylene sulfonate salt, starting from 3,5-difluorosidine and tetrahydrothiopyran-4-one, was described. Antibacterial properties of compound VI were tested against 5 different bacteria, and its MIC values were given.

ACCESSION NUMBER: 2002-793623 HCPLUS

DOCUMENT NUMBER: 1371310923

TITLE: Preparation of oxazolidinones substituted by novel sulfilimine and sulfoximine-containing rings as antibiotics

INVENTOR(S): Bettis, Michael John; Swain, Michael Lingard; Hales, Neil James; Buynik, Hoan Khai

PATENT ASSIGNEE(S): AstraZeneca AB, Sweden; AstraZeneca UK Limited

SOURCE: PCT Int'l. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081470	A1	20021017	WO 2002-GB1644	20020403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GI, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MW, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TU, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IS, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1365844	A1	20040204	EP 2002-720195	20020403
R: NT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531518	T2	20041014	JP 2002-579458	20020403
US 2005032861	A1	20050210	US 2004-480959	20040628
PRIORITY APPLN. INFO.:			GB 2001-8765	A 20010407
			US 2001-330588P	P 20011025
			WO 2002-GB1644	W 20020403

OTHER SOURCE(S): MARPAT 137:310923

IT 471913-40-3P 471913-42-5P 471913-43-5P

471913-46-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(prep. of oxazolidinones substituted by novel sulfilimine and sulfoximine-contg. rings as antibiotics)

RN 471913-40-3 HCPLUS

CN 2H-thiopyran, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 471913-42-5 HCPLUS


CN Benzenesulfonic acid, 2,4,6-trimethyl-, compd. with (5R)-3-[4-(1,1,3,6-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-2-oxazolidinone (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 471913-41-4

CHF C17 H17 F2 N5 O3 S


Absolute stereochemistry.



CH 2

CRN 3453-83-6


CHF C9 H12 O3 S



RN 471913-43-6 HCPLUS

CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-dihydro-1-imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471913-46-9 HCPLUS

CN Thiomorpholine, 1-[(cyanoimino)(methylthio)methyl]imino-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.





IT 471913-44-7P 471913-45-8P 471913-47-0P
 471913-48-1P 471913-49-2P 471913-50-5P
 471913-51-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxazolidinones substituted by novel sulfonimine and sulfonimine-containing rings as antibiotics)

RN 471913-44-7 HCAPLUS

CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-(methylimino)-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-49-2 HCAPLUS

CN 2H-Thiopyran, 1-(acetylimino)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 471913-50-5 HCAPLUS

CN 2H-Thiopyran, 1-(acetylimino)-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,3,6-tetrahydro-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 471913-45-8 HCAPLUS
 CN Thiomorpholine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-1-(methylimino)-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-47-0 HCAPLUS

CN Thiomorpholine, 1-[(cyanooimino)(dimethylamino)methyl]imino)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 471913-48-1 HCAPLUS

CN Thiomorpholine, 1-[(4-amino-5-(methoxycarbonyl)-2-thiazolyl)imino)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1-dihydro-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-51-6 HCAPLUS

CN 2H-Thiopyran, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,1,3,6-tetrahydro-1-[hydroxymethyl]imino-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 371195-00-5P 371195-01-6P 371195-03-8P

371195-04-9P 471913-52-7P 471913-53-8P


471913-54-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones substituted by novel sulfonimine and sulfonimine-containing rings as antibiotics)

RN 371195-00-5 HCAPLUS


L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-01-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-03-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371195-04-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 471913-52-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 471913-53-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 471913-54-9 HCAPLUS
 CN 2H-Thiopyran, 1-[(acetyloxyl)acetyl]imino-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,3,6-tetrahydro-1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ED Entered STN: 02 Nov 2001
 GI



AB The title compds. [I; X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heterocyclic ring containing 2-4 heteroatoms selected from N, O and S, etc.; O = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsubst.) 5-membered heterocyclic ring system or IV; Rc = R13CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.);] useful as antibacterial agents, were prepared and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 μ g/ml against *Staphylococcus aureus* (Oxford), was given.

ACCESSION NUMBER: 20011798227 HCAPLUS

DOCUMENT NUMBER: 135-344473

TITLE: Oxazolidinone derivatives with antibacterial activity

INVENTOR(S): Gravestock, Michael Barry; Betts, Michael John; Griffin, David Alan; Matthews, Ian Richard

PATENT ASSIGNEE(S): AstraZeneca AB, Sweden; AstraZeneca UK Limited

SOURCE: PCT Int'l Appln., 143 pp.

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200101350	A1	20011101	WO 2001-GB1815	20010423
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TN, VN: GH, GM, KG, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-20-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(4-amino-1-piperidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-23-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 BJ, CF, CG, CI, CM, GA, GN, GW, HL, MR, NE, SN, TD, TG
 CA 2405349 AA 20011101 CA 2001-2405349 20010423
 BR 2001010240 A 20030107 BR 2001-10240 20010423
 EP 1286598 A1 20030305 EP 2001-921669 20010423
 EP 1286598 B1 20040609
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MX, CY, AL, TR
 JP 2003531211 T2 20031021 JP 2001-578439 20010423
 KR 200200598 A 20040415 KR 2002-598 20010423
 NZ 521765 A 20040528 NZ 2001-521765 20010423
 AT 268778 E 20040615 AT 2001-921669 20010423
 PT 1286598 T 20040930 PT 2001-921669 20010423
 ES 2220759 T3 20041216 ES 2001-1921669 20010423
 AU 781784 B2 20050616 AU 2001-48636 20010423
 CA 2002008187 A 20040211 CA 2002-8187 20021010
 NO 200200591 A 20021209 NO 2002-5091 20021023
 US 2003216373 A1 20031120 US 2003-258355 20030506
 HK 1053114 A1 20050218 HK 2003-105394 20030725
 PRIORITY APPLN. INFO.: GB 2000-9803 A 20000425
 WO 2001-GB1815 W 20010423

OTHER SOURCE(S): MARPAT 135:344473
 IT 371194-18-2P 371194-19-3P 371194-20-6P
 371194-23-9P 371194-26-2P 371194-34-3P
 371194-35-3P 371194-37-5P 371194-39-7P
 371194-42-2P 371194-57-9P 371194-63-7P
 371194-67-1P 371194-69-3P 371194-71-7P
 371194-73-9P 371194-75-1P 371195-01-6P
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); T (Trade name); (9CI) (CA INDEX NAME)
 RN 371194-18-2 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-19-3 HCAPLUS
 CN 4-Piperidinone, 1-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 371194-26-2 HCAPLUS
 CN Acetamide, 2-(acetyl oxy)-N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-34-2 HCAPLUS
 CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-35-3 HCAPLUS
CN 2-Oxazolidinone, 3-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-37-5 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-39-7 HCAPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-67-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-69-3 HCAPLUS
CN Pyridine, 1-[(acetyl oxy)acetyl]-4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-42-2 HCAPLUS
CN 2-Oxazolidinone, 3-[(3S)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 371194-57-9 HCAPLUS
CN 2-Oxazolidinone, 3-[(methylthio)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-63-7 HCAPLUS




RN 371194-71-7 HCAPLUS
CN Pyridine, 4-[(2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-73-9 HCAPLUS
CN Pyridine, 1-[(acetyl oxy)acetyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-75-1 HCAPLUS
 CN Pyridine, 1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-01-6 HCAPLUS
 CN 2-Oxazolidinone, 3-(4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 371194-21-7P 371194-22-8P 371194-24-0P
 371194-28-1P 371194-27-3P 371194-28-4P
 371194-29-8P 371194-30-8P 371194-31-9P
 371194-32-0P 371194-33-1P 371194-35-4P
 371194-38-6P 371194-40-0P 371194-41-1P
 371194-43-3P 371194-44-4P 371194-45-5P
 371194-46-6P 371194-48-8P 371194-50-1P
 371194-62-6P 371194-64-8P 371194-65-9P
 371194-66-0P 371194-68-2P 371194-70-6P
 371194-72-0P 371194-74-0P 371194-76-2P
 371194-94-4P 371194-95-5P 371194-96-6P
 371194-97-7P 371194-98-8P 371194-99-9P
 371195-00-8P 371195-02-7P 371195-03-8P
 371195-04-9P 371195-17-4P 371195-18-5P
 371195-19-6P 371195-20-9P 371195-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses) (assay/conditions/derivs. with antibacterial activity)


RN 371194-21-7 HCAPLUS
 CN Methanesulfonamide, N-[1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-22-8 HCAPLUS
 CN Carbamic acid, [1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-24-0 HCAPLUS
 CN Methanesulfonamide, N-[1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-25-1 HCAPLUS
 CN Carbamic acid, [1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-4-piperidinyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-27-3 HCAPLUS
 CN Acetamide, N-[1-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]-4-piperidinyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-28-4 HCPLUS
 CN Piperazine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-(2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-29-5 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-

Absolute stereochemistry.




RN 371194-30-9 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-hydroxyethyl)methylamino]acetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-31-9 HCPLUS
 CN Acetamide, N-[2-[(2-[(4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl)-1-piperazinyl]-2-oxoethyl]amino]ethyl]-

Absolute stereochemistry.




RN 371194-32-0 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)methylamino]acetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-33-1 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)amino]acetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-36-4 HCPLUS
 CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-38-6 HCPLUS
 CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, (2S)-2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-40-0 HCPLUS
 CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-


L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-hydroxyethyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-41-1 HCAPLUS
 CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-43-3 HCAPLUS
 CN Acetamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-44-4 HCAPLUS
 CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 371194-59-1 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(1,1-dimethylethyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-62-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 Absolute stereochemistry.




RN 371194-45-5 HCAPLUS
 CN Methanesulfonamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-46-6 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-58-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(methylsulfonyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 371194-64-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-65-9 HCAPLUS
 CN 1(2H)-Pyridinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-66-0 HCAPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-oxazolidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-68-2 HCAPLUS
 CN 1-(2H)-Pyridinecarboxaldehyde, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-70-6 HCAPLUS
 CN Pyridines, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-72-8 HCAPLUS
 CN Pyridine, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-74-0 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-76-2 HCAPLUS
 CN Pyridine, 1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-94-4 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-95-5 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-96-6 HCAPLUS
 CN Pyridine, 1-(ethylsulfonyl)-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-97-7 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-98-8 HCAPLUS
 CN Pyridine, 1-[(3-chloropropyl)sulfonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-99-9 HCAPLUS
 CN Pyridine, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1,2,3,6-tetrahydro-1-[(2-methoxyethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-00-5 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-02-7 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-03-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3,5-difluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-04-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[(4-(3,6-dihydro-2H-thiopyran-4-yl)-3,5-difluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-17-4 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-(4-morpholinylacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-18-5 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-hydroxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-21-0 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 371196-57-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxazolidinone derivs. with antibacterial activity)
 RN 371196-57-5 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-19-6 HCPLUS
 CN Acetamide, N-[2-[(2-[(4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-20-9 HCPLUS
 CN Piperazine, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-[(2-methoxyethyl)methylamino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 371195-29-8P 371195-30-1P 371195-31-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (oxazolidinone derivs. with antibacterial activity)
 RN 371195-29-8 HCPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-30-1 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-31-2 HCAPLUS
 CN Pipecazine, 1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB The synthesis and structure/activity studies of the effect of varying the B group in a series of oxazolidinone antibiotics I (R = Me2CH, Me, SO2, Ac, etc.; R1 = B = H, Me, OH, NHAc, etc.) are described. Two synthetic routes were used: (1) alkylatation of aniline with glycidol followed by dialkyl carbonates heterocyclization to afford I (R = H, R1 = C1bond. = OH), whose arene ring was further elaborated by using electrophilic aromatic substitution methods. (2) cycloaddition of substituted aryl isocyanates with epoxides. I with B = OH or B = Me were converted to other B functionalities by using SN2 methanol. Antibacterial evaluation of compds. I with R = acetyl, iso-Pr, methylthio, methylsulfinyl, methylsulfonyl, and sulfonamido and a variety of different β groups against *Staphylococcus aureus* and *Enterococcus faecalis* concluded that the compds. with B = aminoacyl, and particularly acetamido, were the most active of those examined in each R series, possessing MIC's in the range of 0.5-4 μ g/ml for the most active compds. described.

ACCESSION NUMBER: 1989:457600 HCAPLUS

DOCUMENT NUMBER: 111:57600

TITLE: Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxo-oxazolidines. I. The B group
 AUTHOR(S): Gregory, Walter A.; Brittelli, Donald R.; Wang, C. L.; J., Wuonola, Mark A.; McRipley, Ronald J.; Eustice, David C.; Eberly, Virginia S.; Sles, Andrew M.; Forbes, Martin; Bartholomew, P. T.

CORPORATE SOURCE: E. I. du Pont de Nemours and Co., Wilmington, DE, 19898, USA

SOURCE: Journal of Medicinal Chemistry (1989), 32(8), 1673-81
 CODEN: JMCHAR; ISSN: 0022-2623DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:57600IT 121372-95-0
 AB: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PREP (Preparation, preparation and bactericidal activity of)RN 121372-95-0 HCAPLUS
 CN 1H-1,2,3-Triazole-4,5-dicarboxylic acid, 1-[(3-(4-acetylphenyl)-2-oxo-5-oxazolidinyl)methyl]-, dimethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

